0000711404-21-000038 | 10-K | XBRL Viewer

Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Income Statement [Abstract]
Net sales	$ 2,922.5	$ 2,430.9	$ 2,653.4
Cost of sales	966.7	896.1	896.6
Gross profit	1,955.8	1,534.8	1,756.8
Selling, general and administrative expense	1,211.2	992.5	996.2
Research and development expense	92.7	93.3	86.7
Amortization of intangibles	146.1	137.2	145.8
Impairment of intangibles	0.0	0.0	0.4
Gain on sale of an intangible	0.0	0.0	(19.0)
Operating income	505.8	311.8	546.7
Interest expense	23.1	36.8	68.0
Other (income) expense, net	(8.8)	8.5	1.3
Income before income taxes	491.5	266.5	477.4
Provision for income taxes (Note 6)	(2,453.2)	28.1	10.7
Net income	2,944.7	238.4	466.7
Net income attributable to Cooper stockholders	$ 2,944.7	$ 238.4	$ 466.7
Earnings per share (Note 7)
Basic (in dollars per share)	$ 59.80	$ 4.85	$ 9.44
Diluted (in dollars per share)	$ 59.16	$ 4.81	$ 9.33
Number of shares used to compute earnings per share:
Basic (in shares)	49.2	49.1	49.4
Diluted (in shares)	49.8	49.6	50.0

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Statement of Comprehensive Income [Abstract]
Net income	$ 2,944.7	$ 238.4	$ 466.7
Other comprehensive income (loss):
Cash flow hedges, net of tax provision of $8.2 and $(4.1) in fiscal 2021 and fiscal 2020, respectively	26.1	(13.0)	0.0
Change in minimum pension liability, net of tax provision of $7.2, $(4.0) and $(8.0), respectively	22.6	(12.8)	(25.4)
Foreign currency translation adjustment	82.0	0.9	9.0
Other comprehensive income (loss)	130.7	(24.9)	(16.4)
Comprehensive income	3,075.4	213.5	450.3
Comprehensive income attributable to Cooper stockholders	$ 3,075.4	$ 213.5	$ 450.3

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

+ Details

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Statement of Comprehensive Income [Abstract]
Cash flow hedges, tax provision (benefit)	$ 8.2	$ (4.1)
Change in minimum pension liability, tax provision (benefit)	$ 7.2	$ (4.0)	$ (8.0)

Consolidated Balance Sheets - USD ($) $ in Millions	Oct. 31, 2021	Oct. 31, 2020
Current assets:
Cash and cash equivalents	$ 95.9	$ 115.9
Trade accounts receivable, net of allowance for doubtful accounts of $9.2 at October 31, 2021 and $10.2 at October 31, 2020	515.3	435.4
Inventories (Note 1)	585.6	570.4
Prepaid expense and other current assets	179.3	152.5
Assets held-for-sale (Note 3)	89.2	0.0
Total current assets	1,465.3	1,274.2
Property, plant and equipment, at cost (Note 1)	2,655.7	2,474.8
Less: accumulated depreciation and amortization	1,308.1	1,192.9
Property, plant and equipment, net	1,347.6	1,281.9
Operating lease right-of-use assets (Note 2)	257.0	260.2
Goodwill (Note 4)	2,574.0	2,447.3
Other intangibles, net (Note 4)	1,271.5	1,289.0
Deferred tax assets	2,546.6	80.1
Other assets	144.2	104.8
Total assets	9,606.2	6,737.5
Current liabilities:
Short-term debt (Note 5)	82.9	409.3
Accounts payable	161.4	176.0
Employee compensation and benefits	148.7	119.0
Operating lease liabilities (Note 2)	35.7	33.3
Other current liabilities	301.7	266.8
Liabilities held-for-sale (Note 3)	1.7	0.0
Total current liabilities	732.1	1,004.4
Long-term debt (Note 5)	1,396.1	1,383.9
Deferred tax liabilities	24.1	25.8
Long-term tax payable	139.6	162.0
Operating lease liabilities (Note 2)	231.7	236.8
Accrued pension liability and other	140.6	99.8
Total liabilities	2,664.2	2,912.7
Contingencies (see Note 12)
Stockholders’ equity:
Preferred stock, $10 cents par value, 1.0 shares authorized, zero shares issued or outstanding	0.0	0.0
Common stock, $10 cents par value, 120.0 shares authorized, 53.7 issued and 49.3 outstanding at October 31, 2021 and 53.4 issued and 49.1 outstanding at October 31, 2020	5.4	5.3
Additional paid-in capital	1,715.2	1,646.8
Accumulated other comprehensive loss	(341.3)	(472.0)
Retained earnings	6,202.1	3,261.8
Treasury stock at cost: 4.4 shares at October 31, 2021 and 4.3 shares at October 31, 2020	(639.6)	(617.3)
Total Cooper stockholders' equity	6,941.8	3,824.6
Noncontrolling interests	0.2	0.2
Stockholders’ equity (Note 8)	6,942.0	3,824.8
Total liabilities and stockholders’ equity	$ 9,606.2	$ 6,737.5

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Oct. 31, 2021	Oct. 31, 2020
Statement of Financial Position [Abstract]
Trade accounts receivable, allowance for doubtful accounts	$ 9.2	$ 10.2
Preferred stock, par value (in dollars per share)	$ 0.10	$ 0.10
Preferred stock, authorized (in shares)	1,000,000.0	1,000,000.0
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.10	$ 0.10
Common stock, authorized (in shares)	120,000,000.0	120,000,000.0
Common stock, issued (in shares)	53,700,000	53,400,000
Common stock, outstanding (in shares)	49,300,000	49,100,000
Treasury stock (in shares)	4,400,000	4,300,000

Consolidated Statements of Stockholders' Equity - USD ($) $ in Millions	Total	Common Shares	Treasury Stock	Treasury Stock Par Net Value	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings	Noncontrolling Interests	Cumulative Effect, Period of Adoption, Adjustment	Cumulative Effect, Period of Adoption, Adjustment Retained Earnings
Beginning balance (in shares) at Oct. 31, 2018		49,200,000	3,600,000
Beginning balance at Oct. 31, 2018	$ 3,307.8	$ 5.0	$ (415.1)	$ 0.3	$ 1,572.1	$ (430.7)	$ 2,576.0	$ 0.2	$ (13.3)	$ (13.3)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to Cooper stockholders	466.7						466.7
Other comprehensive income (loss), net of tax	(16.4)					(16.4)
Issuance of common stock for stock plans, net (in shares)		400,000
Issuance of common stock for stock plans, net	7.8				7.8
Treasury stock repurchase (in shares)		500,000	500,000
Treasury stock repurchase	(156.1)	$ (0.1)	$ (156.1)	0.1
Dividends on common stock ($0.03 per share)	(3.0)						(3.0)
Share-based compensation expense	35.1				35.1
Ending balance (in shares) at Oct. 31, 2019		49,100,000	4,100,000
Ending balance at Oct. 31, 2019	3,628.6	$ 4.9	$ (571.2)	0.4	1,615.0	(447.1)	3,026.4	0.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to Cooper stockholders	238.4						238.4
Other comprehensive income (loss), net of tax	(24.9)					(24.9)
Issuance of common stock for stock plans, net (in shares)		200,000
Issuance of common stock for stock plans, net	(6.8)				(6.8)
Issuance of common stock for employee stock purchase plan	$ 3.5		$ 1.7		1.8
Treasury stock repurchase (in shares)	160,850	200,000	200,000
Treasury stock repurchase	$ (47.8)		$ (47.8)
Dividends on common stock ($0.03 per share)	(3.0)						(3.0)
Share-based compensation expense	$ 36.8				36.8
Ending balance (in shares) at Oct. 31, 2020	49,100,000	49,100,000	4,300,000
Ending balance at Oct. 31, 2020	$ 3,824.8	$ 4.9	$ (617.3)	0.4	1,646.8	(472.0)	3,261.8	0.2	$ (1.4)	$ (1.4)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible Enumeration]	us-gaap:AccountingStandardsUpdate201613Member
Net income attributable to Cooper stockholders	$ 2,944.7						2,944.7
Other comprehensive income (loss), net of tax	130.7					130.7
Issuance of common stock for stock plans, net (in shares)		300,000
Issuance of common stock for stock plans, net	20.5	$ 0.1			20.4
Issuance of common stock for employee stock purchase plan	$ 6.7		$ 2.5		4.2
Treasury stock repurchase (in shares)	69,622	100,000	100,000
Treasury stock repurchase	$ (24.8)		$ (24.8)
Dividends on common stock ($0.03 per share)	(3.0)						(3.0)
Share-based compensation expense	$ 43.8				43.8
Ending balance (in shares) at Oct. 31, 2021	49,300,000	49,300,000	4,400,000
Ending balance at Oct. 31, 2021	$ 6,942.0	$ 5.0	$ (639.6)	$ 0.4	$ 1,715.2	$ (341.3)	$ 6,202.1	$ 0.2

Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares					12 Months Ended
	Aug. 11, 2021	Feb. 09, 2021	Aug. 07, 2020	Feb. 10, 2020	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Statement of Stockholders' Equity [Abstract]
Dividends on common stock (in dollars per share)	$ 0.03	$ 0.03	$ 0.03	$ 0.03	$ 0.03	$ 0.03	$ 0.03

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Cash flows from operating activities:
Net income	$ 2,944.7	$ 238.4	$ 466.7
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	309.3	287.1	280.8
Impairment of intangibles	0.0	0.0	0.4
Gain on sale of an intangible	0.0	0.0	(19.0)
Share-based compensation expense	43.8	37.6	35.1
Inventory step-up release	2.0	0.0	0.1
Non-cash operating lease expense	31.8	32.5	0.0
Impairment and loss on disposal of property, plant and equipment, and other	(3.1)	24.4	7.7
Change in fair value of contingent consideration	66.1	0.0	0.0
Deferred income taxes	(2,502.2)	(0.9)	(15.9)
Provision for doubtful accounts	(2.5)	(6.2)	(2.6)
Cloud computing arrangements cost amortization	2.0	0.5	0.0
Interest income on convertible note	(3.4)	(1.0)	0.0
Interest income on convertible note
Accounts receivable	(75.5)	8.5	(55.6)
Inventories	(9.2)	(62.3)	(37.3)
Other assets	(69.1)	(41.1)	39.8
Operating lease right-of-use assets and liabilities, net	(27.5)	(20.0)	0.0
Accounts payable	(16.0)	23.2	3.6
Accrued liabilities	59.1	(9.3)	33.1
Accrued income taxes	10.0	(12.4)	8.7
Other long-term liabilities	(21.7)	(12.4)	(32.4)
Net cash provided by operating activities	738.6	486.6	713.2
Cash flows from investing activities:
Purchases of property, plant and equipment	(214.4)	(310.4)	(292.1)
Acquisitions of businesses and assets, net of cash acquired, and other	(235.9)	(54.1)	(59.2)
Net cash used in investing activities	(450.3)	(364.5)	(351.3)
Cash flows from financing activities:
Proceeds from long-term debt	1,427.5	3,205.4	1,136.8
Repayments of long-term debt	(1,416.0)	(3,235.9)	(1,861.8)
Net (repayments of) proceeds from short-term debt	(321.3)	(6.6)	525.3
Repurchase of common stock	(24.8)	(47.8)	(156.1)
Proceeds related to share-based compensation awards	33.7	13.5	29.9
Payments related to share-based compensation awards	(13.2)	(20.3)	(22.1)
Dividends on common stock	(3.0)	(3.0)	(3.0)
Issuance of common stock for employee stock purchase plan	5.8	2.7	0.0
Debt acquisition costs	(0.1)	(5.6)	(0.4)
Proceeds from construction allowance	0.0	2.1	0.0
Net cash used in financing activities	(311.4)	(95.5)	(351.4)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	2.9	0.7	(1.2)
Net (decrease) increase in cash, cash equivalents, restricted cash and cash held for sale	(20.2)	27.3	9.3
Cash, cash equivalents and restricted cash at beginning of year	116.8	89.5	80.2
Cash, cash equivalents, restricted cash and cash held for sale at end of year	96.6	116.8	89.5
Supplemental disclosures of cash flow information:
Interest	28.4	46.5	75.3
Income taxes	63.2	51.1	39.2
Reconciliation of cash flow information:
Cash and cash equivalents	95.9	115.9	89.0
Restricted cash included in other current assets	0.4	0.9	0.5
Cash held for sale	0.3	0.0	0.0
Total cash, cash equivalents, restricted cash and cash held for sale	$ 96.6	$ 116.8	$ 89.5

Accounting Policies

12 Months Ended

Oct. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Accounting Policies

General

The Cooper Companies, Inc. (Cooper, we or the Company) is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical.

•CooperVision primarily develops, manufactures and markets a broad range of soft contact lenses for the worldwide vision correction market.

•CooperSurgical primarily develops, manufactures, markets medical devices and procedures solutions, and provides services to improve health care delivery to women, babies and families.

Estimates

The World Health Organization categorized the Coronavirus disease 2019 (COVID-19) as a pandemic. The COVID-19 pandemic has caused a severe global health crisis, along with economic and societal disruptions and uncertainties, which have negatively impacted business and healthcare activity globally. As a result of healthcare systems responding to the demands of managing the pandemic, governments around the world imposing measures designed to reduce the transmission of the COVID-19 virus, and individuals responding to the concerns of contracting the COVID-19 virus, many optical practitioners & retailers, hospitals, medical offices and fertility clinics closed their facilities, restricted access, or delayed or canceled patient visits, exams and elective medical procedures, and many customers that have reopened are experiencing reduced patient visits. These factors have had, and in the future may have, an adverse effect on our sales, operating results and cash flows.

The preparation of Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of net sales and expenses during the reporting period. Actual results could differ from those estimates particularly as it relates to estimates reliant on forecasts and other assumptions reasonably available to the Company and the uncertain future impacts of the COVID-19 pandemic and related economic disruptions. The extent to which the COVID-19 pandemic and related economic disruptions impact our business and financial results will depend on future developments including, but not limited to, the continued spread, duration and severity of the COVID-19 pandemic; the occurrence, spread, duration and severity of any subsequent wave or waves of outbreaks, including the emergence and spread of variants of the COVID-19 virus; the actions taken by the U.S. and foreign governments to contain the COVID-19 pandemic, address its impact or respond to the reduction in global and local economic activity; the occurrence, duration and severity of a global, regional or national recession, depression or other sustained adverse market event; the impact of the developments described above on our customers and suppliers; and how quickly and to what extent normal economic and operating conditions can resume. The accounting matters assessed included, but were not limited to:

•allowance for doubtful accounts and credit losses

•the carrying value of inventory

•the carrying value of goodwill and other long-lived assets

There was not a material impact to the above estimates in the Company’s Consolidated Financial Statements for fiscal 2021. The Company continually monitors and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other

factors, could result in material changes to the estimates and material impacts to the Company’s Consolidated Financial Statements in future reporting periods.

Significant Accounting Policies

Management's significant accounting policies include estimates and judgments which are an integral part of financial statements prepared in accordance with accounting principles generally accepted in the United States (GAAP). We believe that the accounting policies described in this section address the more significant policies utilized by management when preparing our consolidated financial statements in accordance with GAAP. We believe that the accounting policies and estimates employed are appropriate and resulting balances are reasonable; however, actual results could differ from the original estimates, requiring adjustment to these balances in future periods. The accounting policies that reflect our more significant estimates, judgments and assumptions and which we believe are the most important to aid in fully understanding and evaluating our reported financial results are:

•Revenue recognition

Net Sales

The Company sells its products principally to a limited number of distributors, group purchasing organizations, eye care or health care professionals including independent practices, corporate retailers, hospitals and clinics or authorized resellers (collectively, its Customers). These Customers subsequently resell the Company’s products to eye care or health care providers and patients. In addition to product supply and distribution agreements with Customers, the Company enters into arrangements with health care providers and payors that provide for government-mandated and/or privately negotiated rebates, chargebacks and discounts with respect to the purchase of the Company’s products. The Company considers customer purchase orders, which in some cases are governed by master sales agreements, to be contracts with a customer. In situations where sales are to a distributor, the Company has concluded that its contracts are with the distributor. As part of its consideration of the contract, the Company evaluates certain factors including the customer’s ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations.

Revenues from product sales are recognized when the Customer obtains control of the Company’s product, which occurs at a point in time, typically upon shipment or delivery to the Customer. When the Company performs shipping and handling activities after the transfer of control to the Customer (e.g., when control transfers prior to delivery), they are considered as fulfillment activities, and accordingly, the costs are accrued for when the related revenue is recognized. Taxes collected from Customers relating to product sales and remitted to governmental authorities are excluded from revenues. The Company does not have any revenue recognized on payment expected to be received more than one year after the transfer of control of the products. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that the Company would have recognized is one year or less. See Note 13. Business Segment Information for disaggregation of revenue.

Reserves for Variable Consideration

Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from discounts, returns, chargebacks, rebates and other allowances that are offered within contracts between the Company and its Customers, health care providers, payors and other indirect customers relating to the Company’s sales of its products. These reserves are based on the amounts earned or to be claimed on the related sales and are classified primarily in current liabilities. Variable consideration is estimated based on the most likely amount or expected value approach, depending on which method the

Company expects to better predict the amount of consideration to which it will be entitled. Once the Company elects one of the methods to estimate variable consideration for a particular type of performance obligation, the Company applies that method consistently.

Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.

Trade Discounts and Allowances

The Company generally provides Customers with discounts, which include incentive fees that are stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company receives sales order management, data and distribution services from certain Customers. To the extent the services received are distinct from the Company’s sale of products to the Customer and have readily determinable fair value, these payments are classified in selling, general and administrative expenses in our Consolidated Statements of Income.

Product Returns

Consistent with industry practice, the Company generally offers Customers a limited right of return for a product that has been purchased from the Company. The Company estimates the amount of its product sales that may be returned by its Customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. There is inherent judgment in estimating future refunds as they are susceptible to factors outside of our influence. However, we have significant experience in estimating the amount of refunds, based primarily on historical data. Our refund liability for product returns was $13.7 million and $10.0 million at October 31, 2021 and 2020, respectively, which is included in Accrued Liabilities on our Consolidated Balance Sheets and represents the expected value of the aggregate refunds that will be due to our customers.

Rebates and Chargebacks

Rebates are estimated based on contractual terms, historical experience, customer mix, trend analysis and projected market conditions in the various markets served.

Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list wholesale prices charged to the Company’s direct customers. For certain office and surgical products in CooperSurgical, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers. CooperSurgical rebates are predominately related to the Medicaid rebate provision that is estimated based upon contractual terms, historical experience, and trend analysis.

Contract balances

The timing of billing and revenue recognition primarily occurs simultaneously. The Company does not have material contract assets or liabilities.

•Leases - We consider an arrangement a lease if the arrangement transfers the right to control the use of an identified asset in exchange for consideration. We have operating leases, but do not have material financing leases. Lease right-of-use assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make payments arising from the lease agreement. These assets and liabilities are recognized at the commencement of the lease based upon the present value of the future minimum lease payments over the lease term. The lease term reflects the noncancellable period of the lease together with periods covered by an option to extend or terminate the lease when management is reasonably certain that it will exercise such option. Changes in the lease term assumption could impact the right-of-use assets and lease liabilities recognized on the Consolidated Balance Sheets. As our leases typically do not contain a readily determinable implicit rate, we determine the present value of the lease liability using our incremental borrowing rate at the lease commencement date based on the lease term on a collateralized basis.

•Net realizable value of inventory - In assessing the value of inventories, we make estimates and judgments regarding aging of inventories and other relevant issues potentially affecting the salable condition of products and estimated prices at which those products will sell. On an ongoing basis, we review the carrying value of our inventory, measuring number of months on hand and other indications of salability. We reduce the value of inventory if there are indications that the carrying value is greater than net realizable value, resulting in a new, lower-cost basis for that inventory. Subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis. While estimates are involved, historically, obsolescence has not been a significant factor due to long product dating and lengthy product life cycles.

•Valuation of goodwill - We evaluate goodwill for impairment annually during the fiscal third quarter and when an event occurs or circumstances change such that it is reasonably possible that impairment may exist. We account for goodwill and evaluate our goodwill balances and test them for impairment in accordance with related accounting standards. We performed our annual impairment test in our third quarter of fiscal 2021 and 2020, and our analysis indicated that we had no impairment of goodwill in our reporting units.

Goodwill impairment analysis and measurement is a process that requires significant judgment. If our common stock price trades below book value per share, there are changes in market conditions or a future downturn in our business, or a future goodwill impairment test indicates an impairment of our goodwill, we may have to recognize a non-cash impairment of goodwill that could be material and could adversely affect our results of operations in the period recognized and also adversely affect our total assets and stockholders' equity.

We test goodwill impairment in accordance with ASU 2017-04, Intangibles - Goodwill and other (Topic 350): Simplifying the Test for Goodwill Impairment. We perform a qualitative assessment to test each reporting unit's goodwill for impairment. Qualitative factors considered in this assessment include industry and market considerations, overall financial performance and other relevant events and factors affecting each reporting unit. Based on our qualitative assessment, if we determine that the fair value of a reporting unit is more likely than not to be less than its carrying amount, the fair value of a reporting unit will be compared with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value of the reporting unit. A reporting unit is the level of reporting at which goodwill is tested for impairment.

•Business combinations - We routinely consummate business combinations. Results of operations for acquired companies are included in our consolidated results of operations from the date of acquisition.

We recognize separately from goodwill, the identifiable assets acquired, including acquired in-process research and development, the liabilities assumed, and any noncontrolling interest in the acquiree at the acquisition date fair values as defined by accounting standards related to fair value measurements. Key assumptions routinely utilized in allocation of purchase price to intangible assets include projected financial information such as revenue projections for companies acquired. As of the acquisition date, goodwill is measured as the excess of consideration given, over the net of the acquisition date fair values of the identifiable assets acquired and the liabilities assumed. Direct acquisition costs are expensed as incurred.

•Income taxes - We account for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and for tax losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.

As part of the process of preparing our consolidated financial statements, we must estimate our income tax expense for each of the jurisdictions in which we operate. This process requires significant management judgments and involves estimating our current tax exposures in each jurisdiction including the impact, if any, of additional taxes resulting from tax examinations as well as judging the recoverability of deferred tax assets. To the extent recovery of deferred tax assets is not likely based on our estimation of future taxable income in each jurisdiction, a valuation allowance is established. Tax exposures can involve complex issues and may require an extended period to resolve. Frequent changes in tax laws in each jurisdiction complicate future estimates. To determine the tax rate, we use the full-year income and the related income tax expense in each jurisdiction. We update the estimated effective tax rate for the effect of significant unusual items as they are identified. Changes in the geographic mix or estimated level of annual pre-tax income can affect the overall effective tax rate, and such changes could be material.

We file income tax returns in all jurisdictions in which we operate. We record a liability for uncertain tax positions taken or expected to be taken in income tax returns that we have determined are not more-likely-than-not realizable. Our financial statements reflect expected future tax consequences of such positions presuming the taxing authorities' full knowledge of the position and all relevant facts. These tax reserves have been established based on management's assessment as to the potential exposure attributable to our uncertain tax positions as well as interest and penalties attributable to these uncertain tax positions. All tax reserves are analyzed quarterly and adjustments are made as events occur that result in changes in judgment.

•Share-Based Compensation - We grant various share-based compensation awards, including stock options, performance unit shares, restricted stock and restricted stock units. Under fair value recognition provisions, share-based compensation expense is measured at the grant date based on the fair value of the award and is recognized as expense over the vesting period. Determining the fair value of share-based awards at the grant date requires judgment, including estimating Cooper's stock price volatility, employee exercise behaviors and related employee forfeiture rates.

The expected life of the share-based awards is based on the observed and expected time to post-vesting forfeiture and/or exercise. Groups of employees that have similar historical exercise behavior are considered separately for valuation purposes. In determining the expected volatility, management considers implied volatility from publicly-traded options on Cooper's common stock at the date of grant, historical volatility and other factors. The risk-free interest rate is based on the continuous rates

provided by the United States Treasury with a term equal to the expected life of the award. The dividend yield is based on the projected annual dividend payment per share, divided by the stock price at the date of grant.

As share-based compensation expense recognized in our Consolidated Statements of Income is based on awards ultimately expected to vest, the amount of expense has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant, based on historical experience, and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

If factors change and we employ different assumptions in the application of the fair value recognition provisions, the compensation expense that we record in future periods may differ significantly from what we have recorded in the current period.

Accounting Pronouncements Recently Adopted

In January 2020, the Financial Accounting Standards Board (FASB) issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)—Clarifying the Interactions between Topic 321, Topic 323, and Topic 815. This guidance addresses accounting for the transition into and out of the equity method and provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. This standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2020. Early adoption is permitted. The Company early adopted this guidance in the second quarter of fiscal 2021, and it did not have a material impact on our Consolidated Financial Statements.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments and subsequent amendments to the initial guidance: ASU 2018-19 Codification Improvements to Topic 326, Financial Instruments-Credit Losses, ASU 2019-04 Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, ASU 2019-05 Financial Instruments-Credit Losses, ASU 2019-11 Codification Improvements to Topic 326, Financial Instruments—Credit Losses, ASU 2020-02 Financial Instruments—Credit Losses (Topic 326) and Leases (Topic 842) and ASU 2020-03 Codification Improvements to Financial Instruments (collectively, “Topic 326”). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. Topic 326 is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2019. The Company adopted this guidance in the first quarter of fiscal 2021 on a modified retrospective basis, and the most notable impact was related to the assessment of the adequacy of its allowance for doubtful accounts on trade accounts receivable and the recognition of credit losses. The Company recorded a cumulative-effect adjustment of $1.4 million to the Consolidated Balance Sheets on November 1, 2020.

In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606. This guidance amended Topic 808 and Topic 606 to clarify that transactions in a collaborative arrangement should be accounted for under Topic 606 when the counterparty is a customer for a distinct good or service (i.e., unit of account). The amendments preclude an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. This guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2019. The Company adopted this guidance on November 1, 2020, and it did not have a material impact on our Consolidated Financial Statements.

Accounting Pronouncements Issued Not Yet Adopted

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for

Income Taxes. This guidance removes certain exceptions to the general principles in Topic 740 and enhances and simplifies various aspects of the income tax accounting guidance, including requirements such as tax basis step-up in goodwill obtained in a transaction that is not a business combination, ownership changes in investments, and interim-period accounting for enacted changes in tax law. This standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2020. Early adoption is permitted. We are currently evaluating the impact of ASU 2019-12 on our Consolidated Financial Statements, which is effective for the Company in our fiscal year and interim periods beginning on November 1, 2021.

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting and subsequent amendment to the initial guidance: ASU 2021-01, Reference Rate Reform (Topic 848): Scope (collectively, “Topic 848”). Topic 848 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The guidance generally can be applied from March 12, 2020 through December 31, 2022. We are currently assessing the impacts of the practical expedients provided in Topic 848 and which, if any, we will adopt.

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). This update amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity's own equity and improves and amends the related EPS guidance for both Subtopics. This standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2021, which means it will be effective for our fiscal year beginning November 1, 2022. Early adoption is permitted but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. We are currently evaluating the impact of ASU 2020-06 on our Consolidated Financial Statements.

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This update requires that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. This standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2022 and should be applied prospectively to business combinations occurring on or after the effective date of the standard. Early adoption is permitted, including adoption in an interim period. We are currently evaluating the impact of ASU 2021-08 on our Consolidated Financial Statements.

In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. This update requires annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. This standard is effective for fiscal years beginning after December 15, 2021 and should be applied either prospectively or retrospectively. Early adoption is permitted. We are currently evaluating the impact of ASU 2021-10 on our Consolidated Financial Statements.

No other recently issued accounting pronouncements had or are expected to have a material impact on our Consolidated Financial Statements.

Consolidation

The financial statements in this report include the accounts of all of Cooper's consolidated entities. All significant intercompany transactions and balances are eliminated on consolidation.

Foreign Currency Translation

Most of our operations outside the United States use their local currency as their functional currency. We translate these assets and liabilities into United States dollars at year-end exchange rates. We translate income

and expense accounts at average rates for each month. We record gains and losses from the translation of financial statements in foreign currencies into United States dollars in other comprehensive income. We record gains and losses from changes in exchange rates on transactions denominated in currencies other than each reporting location's functional currency in net income for each period. We recorded in other expense and income a net foreign exchange loss of $5.5 million for fiscal 2021, $1.2 million for fiscal 2020 and $2.2 million for fiscal 2019.

Litigation

We are subject to various legal proceedings, claims, litigation, investigations and contingencies arising out of the ordinary course of business. If we believe the likelihood of an adverse legal outcome is probable and the amount is estimable, we accrue a liability in accordance with accounting guidance for contingencies. We consult with legal counsel on matters related to litigation and seek input both within and outside the Company.

Long-lived Assets

We review long-lived assets held and used, intangible assets with finite useful lives and assets held for sale for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If an evaluation of recoverability is required, the estimated undiscounted future cash flows associated with the asset group are compared to the asset group's carrying amount to determine if a write-down is required. If the undiscounted cash flows are less than the carrying amount, an impairment loss is recorded to the extent that the carrying amount exceeds the fair value. If management has committed to a plan to dispose of long-lived assets, the assets to be disposed of are reported at the lower of carrying amount or fair value less estimated costs to sell.

CooperVision provides optometric practices with in-office lenses used in marketing programs to facilitate efficient and convenient fitting of contact lenses by practitioners. Such lens fitting sets generally consist of a physical binder or rack to store contact lenses and an array of lenses. We record the costs associated with the original fitting set to other long-term assets on our Consolidated Balance Sheets. We amortize such costs over their estimated useful lives to selling, general and administrative expense on our Consolidated Statements of Income. We also expense the cost for lenses provided to practitioners as replenishment for fitting sets in the period shipped to selling, general and administrative expense on our Consolidated Statements of Income.

Cash and Cash Equivalents

The Company considers all short-term, highly liquid investments purchased with maturities of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value.

Inventories


October 31, (In millions)	2021		2020
Raw materials	$	137.7	$	151.0
Work-in-process	14.0		12.4
Finished goods	433.9		407.0
	$	585.6	$	570.4

Inventories are stated at the lower of cost or net realizable value. Cost is computed using standard cost that approximates actual cost, on a first-in, first-out basis.

Property, Plant and Equipment


October 31, (In millions)	2021		2020
Land and improvements	$	20.3	$	19.9
Buildings and improvements	388.0		356.1
Machinery and equipment	1,863.6		1,764.9
Construction in progress	383.8		333.9
Property, plant and equipment, at cost	$	2,655.7	$	2,474.8
Less: Accumulated depreciation	1,308.1		1,192.9
	$	1,347.6	$	1,281.9

Property, plant and equipment are stated at cost. We compute depreciation using the straight-line method in amounts sufficient to write off depreciable assets over their estimated useful lives. We amortize leasehold improvements over their estimated useful lives or the period of the related lease, whichever is shorter. We depreciate buildings over 30 to 40 years and machinery and equipment over 3 to 15 years.

We expense costs for maintenance and repairs and capitalize major replacements, renewals and improvements. We eliminate the cost and accumulated depreciation of depreciable assets retired or otherwise disposed of from the asset and accumulated depreciation accounts and reflect any gains or losses in operations for the period. We had capitalized interest included in construction in progress of $7.8 million and $5.3 million for the years ended October 31, 2021 and 2020, respectively.

Earnings Per Share

We determine basic earnings per share (EPS) by using the weighted average number of shares outstanding. We determine diluted EPS by increasing the weighted average number of shares outstanding in the denominator by the number of outstanding dilutive equity awards using the treasury stock method.

Treasury Stock

We record treasury stock purchases under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. At October 31, 2021 and 2020, the number of shares in treasury was approximately 4.4 million and 4.3 million, respectively. The Company purchased 70 thousand shares during the year ended October 31, 2021 and 161 thousand shares during the year ended October 31, 2020. See Note 8. Stockholders' Equity for additional information on the share repurchase program.

Leases

12 Months Ended

Oct. 31, 2021

Leases [Abstract]

Leases

The Company primarily has operating leases for office, manufacturing and warehouse space, vehicles, and office equipment. The Company's leases expire on various dates between 2022 and 2045, some of which could include options to extend the lease.

Lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As these leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease's commencement date in determining the present value of lease payments. The Company considers information including, but not limited to, the lease term, its credit rating and interest rates of similar debt instruments with comparable credit ratings and security interests. The lease right-of-use assets are increased by any lease prepayments made and reduced by any lease incentives such as tenant improvement allowances. Options to extend the lease term are included in the lease term when it is reasonably certain that the Company will exercise the extension option.

The Company’s operating leases typically include non-lease components such as common-area maintenance costs. The Company has elected to include non-lease components with lease payments for the purpose of calculating lease right-of-use assets and liabilities, to the extent that they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease payments.

Leases with a term of one year or less are not recognized on the Consolidated Balance Sheets, while the associated lease payments are recorded in the Consolidated Statements of Income and Comprehensive Income on a straight-line basis over the lease term.

Commitments under finance lease arrangements of $2.0 million and $2.4 million as of October 31, 2021 and October 31, 2020, respectively, are not significant and are not included in the disclosure tables below.

The following table presents information about leases on the Consolidated Balance Sheets:


October 31, (In millions)	2021			2020
Operating Leases
Operating lease right-of-use assets	$	257.0		$	260.2

Operating lease liabilities, current	35.7			33.3
Operating lease liabilities, non-current	231.7			236.8
Total operating lease liabilities	$	267.4		$	270.1

Weighted average remaining lease term (in years)	10.6			11.3
Weighted average discount rate	3		%	3		%

The following table presents information about lease expense, which is included in selling, general and administrative expenses in the Consolidated Statements of Income:


(In millions)	2021		2020
Operating lease expense	$	44.1	$	41.2
Short-term lease expense	0.9		4.4
Variable lease expense	$	0.4	$	1.8

ASC 840 Comparative Disclosures

Prior to fiscal 2020, we accounted for our leases in accordance with ASC 840, Leases. Under ASC 840, rental expense for operating leases was $45.3 million for fiscal 2019.

Supplemental Cash Flow Information

The following table presents supplemental cash flow information about the Company’s leases:


(In millions)	2021		2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	37.4	$	40.6
Operating lease right-of-use assets obtained in exchange for lease obligations	$	26.5	$	17.7

Maturity of Lease Liabilities

The minimum rental payments required under operating leases that have initial or remaining noncancellable lease terms in excess of one year as of October 31, 2021 are:


(In millions)
2022	$	42.5
2023	37.3
2024	31.9
2025	30.2
2026	29.4
Thereafter	146.3
Total lease payments	$	317.6
Less: interest	50.2
Present value of lease liabilities	$	267.4

Acquisitions and Assets Held for Sale

12 Months Ended

Oct. 31, 2021

Business Combination and Asset Acquisition [Abstract]

Acquisitions and Assets Held for Sale

The following is a summary of the allocation of the total purchase consideration for business and asset acquisitions that the Company completed during fiscal 2021, 2020, and 2019:


(In millions)	2021		2020		2019
Technology	$	178.6	$	—	$	12.3
In-Process Research & Development (IPR&D)	20.0		—		—
Customer relationships	7.5		11.4		7.5
Trademarks	1.3		5.1		10.2
Other	0.6		3.9		0.1
Total identifiable intangible assets	$	208.0	$	20.4	$	30.1

Goodwill	91.6		15.3		29.8
Net tangible (liabilities) assets	(10.8)		(0.3)		7.3
Fair value of contingent consideration	(39.1)		—		—
Total closing purchase price	$	249.7	$	35.4	$	67.2

All acquisitions were funded by cash generated from operations or facility borrowings.

For business acquisitions, the Company recorded tangible and intangible assets acquired and liabilities assumed at their fair values as of the applicable date of acquisition. For asset acquisitions, the Company recorded tangible and intangible assets acquired and liabilities assumed at their estimated and relative fair values as of the applicable date of acquisition.

The Company believes these acquisitions strengthen CooperSurgical's and CooperVision's businesses through the addition of new distributors or complementary products and services.

Fiscal Year 2021

On May 3, 2021, CooperSurgical completed the acquisition of a privately-held medical device company that develops single-use illuminating medical devices. The purchase price allocation is preliminary, and the Company is in the process of finalizing information primarily related to the valuation of intangible assets and inventory, the associated deferred tax adjustments and the corresponding impact on goodwill.

On April 26, 2021, CooperVision completed the acquisition of a privately-held UK contact lens manufacturer focusing on specialty contact lenses. This acquisition expands CooperVision’s specialty eye care portfolio and accelerates its development of myopia management solutions in the UK.

On March 1, 2021, CooperSurgical completed the acquisition of a privately-held medical device company that designed and developed an innovative obstetric product for use in urgent obstetrics to reduce risks associated with childbirth. The purchase price allocation is preliminary, and the Company is in the process of finalizing information primarily related to the valuation of intangible assets, the associated deferred tax adjustments and the corresponding impact on goodwill.

On February 1, 2021, CooperSurgical acquired all of the remaining equity interests of a privately-held medical device company that developed the Mara® Water Vapor Ablation System, which is used for endometrial ablation. The Company accounted for this acquisition as an asset acquisition, whereby the Company allocated the total cost of the acquisition to the net assets acquired on the basis of their estimated relative fair values on the acquisition date with no goodwill recognized. The primary asset acquired in this asset acquisition is Technology.

On January 19, 2021, CooperVision acquired all of the remaining equity interests of a privately-held medical device company that develops spectacle lenses for myopia management. The fair value remeasurement of our previous equity investment immediately before the acquisition resulted in a gain of $11.5 million, which was recorded in other income. The terms of the acquisition include upfront cash consideration paid at closing of approximately $40.9 million attributable to the equity interests not held by the Company on the closing date. The transaction also includes potential payments of future consideration that are contingent upon the achievement of the regulatory approval milestone (the regulatory approval payment) and the acquired business reaching certain revenue thresholds over a specified period (the revenue payments). The undiscounted range of the contingent consideration is zero to $139.1 million payable to the other former equity interest owners.

The estimated fair value of the contingent consideration on the acquisition date was approximately $37.9 million, and, accordingly, the Company recorded a liability of approximately $30.2 million, which represents the fair value of the contingent consideration payable to the other former equity interest owners. The fair value of the regulatory approval payment was determined using an option pricing framework based on the expected payment under the contractual terms and the estimates of the probability of achieving the regulatory approval. The fair value of the revenue payments was determined using a Monte Carlo simulation based on the revenue projections and the expected payment for each simulation.

As of October 31, 2021, no contingent consideration has been paid. The Company remeasured the fair value of the contingent consideration at each reporting period. In fiscal 2021, a $56.8 million expense was recognized in selling, general and administrative expense in the Consolidated Statements of Income, resulting from the increase in fair value of the contingent consideration. This was primarily driven by increases in revenue projections, which increased the estimated fair value of the revenue payments.

On December 31, 2020, CooperSurgical completed the acquisition of a privately-held in vitro fertilization (IVF) cryo-storage software solutions company.

The pro forma results of operations of these acquisitions have not been presented because the effect of the business combinations described above was not material to the consolidated results of operations.

Subsequent Events

On November 6, 2021, subsequent to the fiscal year ended October 31, 2021, CooperSurgical entered into an Agreement and Plan of Merger (the “Merger Agreement”) to acquire Generate Life Sciences, a privately held leading provider of donor egg and sperm for fertility treatments, fertility cryopreservation services and newborn stem cell (cord blood and cord tissue) storage. The aggregate consideration is $1.605 billion in cash,

subject to adjustment as set forth in the Merger Agreement. The transaction is anticipated to close in the first quarter of fiscal 2022 and is subject to customary closing conditions, including regulatory approval.

See Note 15. Subsequent Events for more details.

Fiscal Year 2020

On August 7, 2020, CooperVision completed the acquisition of a privately-held U.S contact lens manufacturer focusing on ortho-k lenses. This acquisition expands CooperVision’s specialty eye care portfolio and its leadership in addressing the increasing severity and prevalence of myopia.

On December 13, 2019, CooperSurgical completed the acquisition of a privately-held distributor of in vitro fertilization (IVF) medical devices and systems.

Fiscal Year 2019

On December 31, 2018, CooperSurgical completed the acquisition of a privately-held U.S. medical device company that develops mechanical surgical solutions for skin closure.

On December 28, 2018, CooperVision completed the acquisition of a privately-held scleral lens company, which expands CooperVision's specialty and scleral lens portfolio.

Contingent Consideration

Certain of the Company’s business combinations involve potential payments of future consideration that are contingent upon the achievement of regulatory milestones and/or the acquired business reaching certain revenue thresholds. A liability is recorded for the estimated fair value of the contingent consideration on the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period, and the change in fair value is recognized in selling, general and administrative expense in the Consolidated Statements of Income.

The following table provides a reconciliation of the beginning and ending balances of contingent consideration:


(In millions)	2021		2020
Beginning balance	$	—	$	—
Purchase price contingent consideration	31.3		—
Payments	—		—
Change in fair value	66.1		—
Ending balance	$	97.4	$	—

Assets Held for Sale

On February 2, 2021, CooperVision entered into a stock purchase agreement to sell 50% of the equity interest in a wholly-owned subsidiary that was acquired by CooperVision on January 19, 2021. The closing of this transaction is subject to certain closing conditions including required regulatory approvals. The Company

intends to operate the previously wholly-owned subsidiary as a joint venture with the purchaser of the 50% interest once the transaction is closed.

The Company concluded the substantive terms of the joint venture during the third quarter of fiscal 2021, and the assets and liabilities of this disposal group were reclassified as held for sale as of July 31, 2021. On August 1, 2021, CooperVision entered into a stockholders agreement, which outlines the terms regarding the operation and management of the joint venture. As of October 31, 2021, the Company was in the process of finalizing the joint venture related ancillary agreements, and the disposal group continues to be classified as held for sale as of October 31, 2021.

Pursuant to ASC 360, assets held for sale were measured at the lower of their carrying amounts or fair value less cost to sell. The Company did not record any impairment in fiscal 2021. The Company has determined that this disposal did not qualify as a discontinued operation as the sale was deemed to not be a strategic shift that has or will have a major effect on the Company's operations and financial results.

Included in the Company's Consolidated Balance Sheets as of October 31,2021 are the following carrying amounts of the assets and liabilities held for sale:


(In millions)	October 31, 2021
ASSETS
Cash	$	0.3
Goodwill	23.2
Other intangibles, net	83.6
Deferred tax assets	(19.9)
Other assets	2.0
Total assets held-for-sale	$	89.2
LIABILITIES
Total liabilities held-for-sale	$	1.7

Intangible Assets

12 Months Ended

Oct. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Goodwill


(In millions)	CooperVision		CooperSurgical		Total
Balance at October 31, 2019	$	1,765.4	$	663.5	$	2,428.9
Net additions	13.5		1.8		15.3
Foreign currency translation adjustment	0.4		2.7		3.1
Balance at October 31, 2020	$	1,779.3	$	668.0	$	2,447.3
Net additions	30.2		61.4		91.6
Amount reclassified to assets held for sale (Note 3)	(23.2)		—		(23.2)
Foreign currency translation adjustment	54.7		3.6		58.3
Balance at October 31, 2021	$	1,841.0	$	733.0	$	2,574.0

Of the October 31, 2021 goodwill balance, $137.2 million for CooperSurgical and $24.6 million for CooperVision is expected to be deductible for tax purposes. Of the October 31, 2020 goodwill balance, $134.2 million for CooperSurgical and $26.9 million for CooperVision was expected to be deductible for tax purposes.

The Company evaluates goodwill for impairment annually during the fiscal third quarter and when an event occurs or circumstances change such that it is reasonably possible that impairment may exist. The Company accounts for goodwill, evaluates and tests goodwill balances for impairment in accordance with related accounting standards.

The Company performed an annual impairment assessment in the third quarter of fiscal 2021 and 2020, and its analysis indicated that there was no impairment of goodwill in its reporting units. Qualitative factors considered in the assessment include industry and market considerations, overall financial performance and other relevant events and factors affecting each reporting unit. Based on the Company's qualitative assessment, if the Company determines that the fair value of a reporting unit is more likely than not to be less than its carrying amount, the fair value of a reporting unit will be compared with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value of the reporting unit. A reporting unit is the level of reporting at which goodwill is tested for impairment. The Company has three reporting units: CooperVision and within the CooperSurgical segment, Office/Surgical and Fertility, reflecting the current way the Company manages its business.

Goodwill impairment analysis and measurement is a process that requires significant judgment. If the Company's common stock price trades below book value per share, there are changes in market conditions or a future downturn in its business, or a future goodwill impairment test indicates an impairment of its goodwill, the Company may have to recognize a non-cash impairment of goodwill that could be material and could adversely affect the Company's results of operations in the period recognized and also adversely affect its total assets and stockholders' equity.

Other Intangible Assets


	October 31, 2021				October 31, 2020
(In millions)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization		Weighted Average Amortization Period (in years)
Intangible assets with definite lives:
Trademarks	$	156.7	$	49.1	$	153.4	$	37.7	14
Composite intangible asset	1,061.8		283.2		1,061.9		212.4		15
Technology	513.0		287.9		401.2		251.9		10
Customer relationships	378.4		240.1		367.0		216.2		13
License and distribution rights and other	33.4		21.6		31.8		18.2		10
	2,143.3		$	881.9	2,015.3		$	736.4	14
Less: accumulated amortization and translation	881.9				736.4
Intangible assets with definite lives, net	$	1,261.4			$	1,278.9
Intangible assets with indefinite lives, net (1)	10.1				10.1
Total other intangibles, net	$	1,271.5			$	1,289.0

(1) Intangible assets with indefinite lives include technology and trademarks.

Balances include foreign currency translation adjustments.

Intangible assets with definite lives are amortized over the estimated useful life of the assets. As of October 31, 2021, the estimate of future amortization expenses for intangible assets with definite lives is as follows:


Fiscal years:	(In millions)
2022	$	149.2
2023	146.9
2024	142.7
2025	132.2
Thereafter	690.4
Total remaining amortization for intangible assets with definite lives	$	1,261.4

The Company assesses definite-lived intangible assets whenever events or changes in circumstances indicate that the carrying amount of a definite-lived intangible asset (asset group) may not be recoverable. When events or changes in circumstances indicate that the carrying amount of a definite-lived intangible asset may not be recoverable, in accordance with related accounting standards, the Company evaluates whether the definite-lived intangible asset is impaired by comparing its carrying value to its undiscounted future cash flows. The Company assesses indefinite-lived intangible assets annually in the third quarter of the fiscal year, or whenever events or circumstances indicate that the carrying amount of an indefinite-lived intangible asset (asset group) may not be recoverable. The Company evaluates whether the indefinite-lived intangible asset is impaired by comparing its carrying value to its fair value.

If the carrying value of a definite-lived or indefinite-lived intangible asset is not recoverable, an impairment loss is recognized based on the amount by which the carrying value exceeds the fair value. The inputs used in the fair value analysis fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. The Company performs impairment tests using an income approach, more specifically a relief from royalty method. In the development of the forecasted cash flows, the Company applies significant management judgment to determine key assumptions, including revenue growth and operating margin growth, royalty rates and discount rates assumptions. Revenue and operating margin growth assumptions are based on historical trends and management’s expectations for future growth. Royalty rates used are consistent with those assumed for the original purchase accounting valuation. The discount rates were based on a weighted-average cost of capital utilizing industry market data of similar companies, in addition to estimated returns on the assets utilized in the operations of the applicable reporting unit, including net working capital, fixed assets and intangible assets. Other assumptions are consistent with those applied to goodwill impairment testing.

Given the general deterioration in economic and market conditions surrounding the COVID-19 pandemic, the Company considered the impact that the COVID-19 pandemic may have on its near and long-term forecasts and determined that it was not more likely than not that the fair value of reporting units or relevant asset groups was below carrying amounts, and therefore the Company determined that there was no impairment to either its goodwill, definite-lived or indefinite-lived intangible assets during fiscal 2021.

Debt

12 Months Ended

Oct. 31, 2021

Debt Disclosure [Abstract]

Debt


October 31, (In millions)	2021		2020


Overdraft and other credit facilities	$	83.0	$	59.4
Term loans	—		350.0
Less: unamortized debt issuance cost	(0.1)		(0.1)
Short-term debt	$	82.9	$	409.3

Revolving credit	$	546.1	$	534.0
Term loans	850.0		850.0
Other	0.2		0.2
Less: unamortized debt issuance cost	(0.2)		(0.3)
Long-term debt	$	1,396.1	$	1,383.9

Total debt	$	1,479.0	$	1,793.2

Fiscal year maturities of long-term debt as of October 31, 2021, are as follows:


Year (In millions)
2022	$	—
2023	$	—
2024	$	—
2025	$	1,396.3
2026	$	—
Thereafter	$	—

Term Loan Agreement on November 2, 2021

On November 2, 2021, subsequent to the fiscal year ended October 31, 2021, the Company entered into a 364-day, $840.0 million, term loan agreement by and among the Company, the lenders party thereto and The Bank of Nova Scotia, as administrative agent, which matures on November 1, 2022. The Company used part of the funds to partially repay outstanding borrowings under the 2020 Revolver Credit Facility and for general corporate purposes. See Note 15. Subsequent Events for additional information.

Term Loan Agreement on October 16, 2020

On October 16, 2020, the Company entered into a 364-day, $350.0 million, term loan agreement by and among the Company, the lenders party thereto and The Bank of Nova Scotia, as administrative agent, which matured on October 15, 2021. At maturity, outstanding amounts under this agreement were fully repaid using borrowings under the 2020 Revolving Credit Facility.

Revolving Credit and Term Loan Agreement on April 1, 2020

On April 1, 2020, the Company entered into a Revolving Credit and Term Loan Agreement (the 2020 Credit Agreement), among the Company, CooperVision International Holding Company, LP, CooperSurgical Netherlands B.V., CooperVision Holding Kft. the lenders from time to time party thereto, and KeyBank National Association, as administrative agent. The 2020 Credit Agreement provides for (a) a multicurrency revolving credit facility (the 2020 Revolving Credit Facility) in an aggregate principal amount of $1.29 billion and (b) a term loan facility (the 2020 Term Loan Facility) in an aggregate principal amount of $850.0 million,

each of which, unless terminated earlier, mature on April 1, 2025. In addition, the Company has the ability from time to time to request an increase to the size of the revolving credit facility or establish one or more new term loans under the term loan facility in an aggregate amount up to $1.605 billion, subject to the discretionary participation of the lenders.

Amounts outstanding under the 2020 Credit Agreement will bear interest, at the Company’s option, at either the base rate, or the adjusted LIBO rate or adjusted foreign currency rate, plus, in each case, an applicable rate of between 0.00% and 0.50% in respect of base rate loans, and between 0.75% and 1.50% in respect of adjusted LIBO rate or adjusted foreign currency rate loans, in each case in accordance with a pricing grid tied to the Total Leverage Ratio, as defined in the 2020 Credit Agreement. During the term of the 2020 Revolving Credit Facility, the Borrowers may borrow, repay and re-borrow amounts available under the Revolving Credit Facility, subject to voluntary reduction of the revolving commitment.

The Company pays an annual commitment fee that ranges from 0.10% to 0.20% of the unused portion of the 2020 Revolving Credit Facility based upon the Company’s Total Leverage Ratio, as defined in the 2020 Credit Agreement. In addition to the annual commitment fee, the Company is also required to pay certain letter of credit and related fronting fees and other administrative fees pursuant to the terms of the 2020 Credit Agreement.

On April 1, 2020, the Company borrowed $850.0 million under the 2020 Term Loan Facility and $445.0 million under the 2020 Revolving Credit Facility and used the proceeds to fully repay all borrowings outstanding under a previously existing term loan agreement and transfer all letters of credit and borrowings outstanding under a previously existing credit agreement to the 2020 Credit Agreement, as further described below.

On October 30, 2020, the Company entered into Amendment No. 1 to the 2020 Credit Agreement (the First Amendment to the 2020 Credit Agreement). The First Amendment to the 2020 Credit Agreement modifies the 2020 Credit Agreement by, among other things, adding CooperVision International Limited as a revolving borrower and releasing certain borrowers in the 2020 Credit Agreement.

At October 31, 2021, the Company had $850.0 million outstanding under the 2020 Term Loan Facility and $546.1 million outstanding under the 2020 Revolving Credit Facility. The interest rate on the 2020 Term Loan Facility was 0.96% at October 31, 2021. The interest rate on the 2020 Revolving Credit Facility was 0.96% at October 31, 2021. In fiscal 2021, the Company expensed $0.1 million related to the debt issuance costs of the 2020 Term Loan Facility.

The 2020 Credit Agreement contains customary restrictive covenants, as well as financial covenants that require the Company to maintain a certain Total Leverage Ratio and Interest Coverage Ratio, each as defined in the 2020 Credit Agreement:

•Interest Coverage Ratio, as defined, to be at least 3.00 to 1.00 at all times.

•Total Leverage Ratio, as defined, to be no higher than 3.75 to 1.00.

At October 31, 2021, the Company was in compliance with the Interest Coverage Ratio at 43.29 to 1.00 and the Total Leverage Ratio at 1.38 to 1.00 for 2020 Credit Agreement. The Company, after considering the potential impacts of the COVID-19 pandemic, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations for at least the twelve months following the date of issuance of these financial statements.

The following is a summary of the maximum commitments and the net amounts available to the Company under the credit facilities discussed above as of October 31, 2021:


(In millions)	Facility Limit		Outstanding Borrowings		Outstanding Letters of Credit		Total Amount Available		Maturity Date
2020 Revolving Credit Facility	$	1,290.0	$	546.1	$	1.3	$	742.6	April 1, 2025
2020 Term Loan Facility	850.0		850.0		n/a		—		April 1, 2025
Total	$	2,140.0	$	1,396.1	$	1.3	$	742.6

European Credit Facilities

The Company maintains European credit facilities in the form of continuing and unconditional guarantees. The aggregate facility limit was $35.8 million and $25.8 million at October 31, 2021 and 2020, respectively. The Company will pay all forms of indebtedness in the currency in which it is denominated for those certain subsidiaries. Interest expense is calculated on all outstanding balances based on an applicable base rate for each country plus a fixed spread common across most subsidiaries covered under the guaranty. At October 31, 2021, $5.4 million of the facilities was utilized. The weighted average interest rate on the outstanding balances was 0.57%.

Asian Pacific Credit Facilities

The Company maintains Yen-denominated credit facilities in Japan supported by continuing and unconditional guarantees. The aggregate facility limit was $95.0 million and $76.6 million at October 31, 2021 and 2020, respectively. The Company will pay all forms of indebtedness in Yen upon demand. Interest expense is calculated on the outstanding balance based on the base rate or TIBOR plus a fixed spread. At October 31, 2021, $77.7 million of the combined facilities was utilized. The weighted average interest rate on the outstanding balances was 0.42%.

The Company maintains credit facilities for certain of our Asia Pacific subsidiaries. Each facility is supported by a continuing and unconditional guaranty. The aggregate facility limit was $9.9 million and $11.2 million at October 31, 2021 and 2020, respectively. The Company will pay all forms of indebtedness, for each facility, in the currency in which it is denominated for those certain subsidiaries. Interest expense is calculated on all outstanding balances based on an applicable base rate for each country plus a fixed spread across all subsidiaries covered under each guaranty. At October 31, 2021, $0.4 million of the facilities was utilized. The weighted average interest rate on the outstanding balances was 2.54%.

Letters of Credit

The Company maintain letters of credit throughout the world with various financial institutions that primarily serve as guarantee notes on certain debt obligations. The aggregate outstanding amount of letters of credit at October 31, 2021 and October 31, 2020 was $4.9 million and $4.5 million, respectively.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Income Taxes

12 Months Ended

Oct. 31, 2021

Income Tax Disclosure [Abstract]

Income Taxes

Effective Tax Rate

The effective tax rates for fiscal 2021 and 2020 were (499.1)% and 10.6%, respectively. The decrease was primarily due to an intra-group transfer of intellectual property, as discussed below, and remeasurement of the related deferred tax assets caused by the UK enactment of a 25% corporate tax rate. The effective tax rate otherwise increased due to changes in the geographical composition of pre-tax earnings, partially offset by changes in foreign earnings subject to US tax.

The effective tax rate for fiscal 2021 was lower than the US federal statutory tax rate primarily due to the intra-group transfer, the remeasurement of deferred tax assets, and earnings in foreign jurisdictions with lower tax rates partially offset by foreign earnings subject to US tax. The effective tax rate for fiscal 2020 was lower than the US federal statutory rate primarily due to foreign earnings in jurisdictions with lower tax rates partially offset by foreign earnings subject to US tax.

In November 2020, the Company completed an intra-group transfer of certain intellectual property and related assets of the CooperVision business to a UK subsidiary as part of a group restructuring to establish headquarters operations in the UK. Determining fair value involved significant judgment related to future revenue growth, operating margins and discount rates. Income before income taxes resulting from this transfer is eliminated upon consolidation. The transfer resulted in a step-up of the UK tax-deductible basis in the intellectual property and goodwill, creating a temporary difference between the book basis and the tax basis of these assets. As a result, the Company recognized a deferred tax asset of $1,987.9 million, with a corresponding income tax benefit, during the three months ended January 31, 2021.

Components of income before income taxes:


Years Ended October 31, (In millions)	2021		2020		2019
Income before income taxes:
United States	$	(31.0)	$	(88.0)	$	(32.8)
Foreign	522.5		354.5		510.2
	$	491.5	$	266.5	$	477.4

Components of provision for income taxes:


Years Ended October 31, (In millions)	2021		2020		2019
Current:
Federal	$	21.0	$	1.4	$	9.2
State	1.3		1.1		1.6
Foreign	26.7		26.5		15.8
	49.0		29.0		26.6

Deferred:
Federal	(8.8)		3.2		(8.1)
State	(0.5)		0.8		(0.9)
Foreign	(2,492.9)		(4.9)		(6.9)
	(2,502.2)		(0.9)		(15.9)
Provision for income taxes	$	(2,453.2)	$	28.1	$	10.7

Reconciliation between the expected provision for income taxes at the US federal statutory rate and the provision for income taxes:


Years Ended October 31, (In millions)	2021		2020		2019
Provision for income taxes at United States statutory tax rate	$	103.2	$	56.0	$	100.3
(Decrease) increase in taxes resulting from:
Foreign income subject to different tax rates	(43.6)		(54.7)		(85.6)
Foreign income subject to United States tax	25.4		32.0		16.1
United States tax reform	—		—		(5.8)
Employee compensation	(9.9)		(4.4)		(7.8)
Deferred tax asset step-up	3.2		(9.0)		(6.7)
United States provision-to-return	(1.2)		7.0		4.4
Intra-group transfer to UK subsidiary	(1,987.9)		—		—
Remeasurement of deferred tax assets from UK rate change	(536.7)		—		—
Change in unrecognized tax benefits	(7.6)		(0.1)		(1.5)
Other, net	1.9		1.3		(2.7)
Actual provision for income taxes	$	(2,453.2)	$	28.1	$	10.7

Components of deferred tax assets and liabilities:


Years Ended October 31, (In millions)	2021		2020
Deferred tax assets:
Accounts receivable, principally due to allowances for doubtful accounts	$	3.4	$	2.6
Inventories	6.1		5.8
Accrued liabilities, reserves and compensation accruals	78.1		77.1
Foreign deferred tax assets	2,531.5		90.9
Share-based compensation	28.6		21.4
Net operating loss carryforwards	18.5		9.6
Intangible assets	7.5		19.6
Research and experimental expenses - Section 59(e)	13.5		9.2
Tax credit carryforwards	0.8		1.5
Total gross deferred tax assets	2,688.0		237.7
Less: valuation allowance	(51.8)		(45.3)
Deferred tax assets	2,636.2		192.4
Deferred tax liabilities:
Tax deductible goodwill	(34.0)		(29.7)
Plant and equipment	(46.5)		(39.2)
Deferred tax on foreign earnings	(8.4)		(7.5)
Transaction costs	(0.7)		(0.7)
Foreign deferred tax liabilities	(24.1)		(61.0)


Total gross deferred tax liabilities	(113.7)		(138.1)
Net deferred tax assets	$	2,522.5	$	54.3

In assessing the realizability of deferred tax assets, the Company analyzes whether some or all deferred tax assets will not be realized. This analysis considers historical taxable income, the projected reversal of deferred tax liabilities, projected taxable income and tax planning strategies. Based upon this analysis, it is more likely than not the deferred tax assets, net of valuation allowance, will be realized. The increase in valuation allowance is primarily due to foreign tax credits.

At October 31, 2021, we had federal net operating loss carryforwards of $63.7 million, state net operating loss carryforwards of $19.7 million, and $1.0 million of California research credit carryforwards. Federal net operating loss carryforwards of $47.5 million expire on various dates between 2025 and 2037 and $16.2 million do not expire. The state net operating loss carryforwards expire on various dates between 2025 through 2043, and the California research credit carryforwards do not expire.

The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized from such positions are estimated based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.

Changes in unrecognized tax benefits:


(In millions)
Balance at October 31, 2019	$	49.7
Increase from prior year's UTB's	3.4
Increase from current year's UTB's	7.6

UTB (decrease) from expiration of statute of limitations	(2.2)

Balance at October 31, 2020	$	58.5
Decrease from prior year's UTB's	(8.3)
Increase from current year's UTB's	307.2
Increase (decrease) from settlements	(1.9)

UTB (decrease) from expiration of statute of limitations	(1.7)

Balance at October 31, 2021	$	353.8

As of October 31, 2021, 2020 and 2019 there were unrecognized tax benefits of $353.8 million, $58.5 million, and $49.7 million, respectively. If recognized, these tax benefits would affect our effective tax rates for 2021, 2020 and 2019, by $336.5 million, $46.0 million, and $41.7 million, respectively. Interest and penalties related to unrecognized tax benefits are recognized as income tax expense. As of October 31, 2021, 2020 and 2019, we had accrued gross interest and penalties related to unrecognized tax benefits of $6.4 million, $7.3 million, and $3.9 million, respectively.

Included in the balance of unrecognized tax benefits at October 31, 2021 is $4.2 million related to tax positions for which it is reasonably possible that the total amounts could significantly change during the next twelve months.

Filed tax returns are subject to examination by tax authorities in major tax jurisdictions after fiscal 2014, including the UK and the US.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Earnings Per Share

12 Months Ended

Oct. 31, 2021

Earnings Per Share [Abstract]

Earnings Per Share


Years Ended October 31,
(In millions, except for earnings per share)	2021		2020		2019
Net income attributable to Cooper stockholders	$	2,944.7	$	238.4	$	466.7
Basic:
Weighted average common shares	49.2		49.1		49.4
Basic earnings per share attributable to Cooper stockholders	$	59.80	$	4.85	$	9.44
Diluted:
Weighted average common shares	49.2		49.1		49.4
Effect of dilutive stock plans	0.6		0.5		0.6
Diluted weighted average common shares	49.8		49.6		50.0
Diluted earnings per share attributable to Cooper stockholders	$	59.16	$	4.81	$	9.33

The following table sets forth stock options to purchase our common stock and restricted stock units that were not included in the diluted earnings per share calculation because their effect would have been antidilutive for the periods presented:


Years Ended October 31,
(In thousands, except exercise prices)	2021		2020		2019
Stock option shares excluded	107		207		198
Exercise prices	$	345.74	$	304.54	$	254.77
Restricted stock units excluded	2		1		8

Stockholders' Equity

12 Months Ended

Oct. 31, 2021

Stockholders' Equity Note [Abstract]

Stockholders' Equity

Stockholders’ Equity

Analysis of Changes in Accumulated Other Comprehensive Income (Loss):


(In millions)	Foreign Currency Translation Adjustment		Derivatives		Minimum Pension Liability		Total
Balance at October 31, 2018	$	(412.2)	$	—	$	(18.5)	$	(430.7)
Gross change in value	9.0		—		(33.4)		(24.4)
Tax effect	—		—		8.0		8.0

Balance at October 31, 2019	$	(403.2)	$	—	$	(43.9)	$	(447.1)
Gross change in value	$	0.9	$	(17.1)	$	(16.8)	$	(33.0)
Tax effect	—		4.1		4.0		8.1

Balance at October 31, 2020	$	(402.3)	$	(13.0)	$	(56.7)	$	(472.0)
Gross change in value	$	82.2	$	34.3	$	29.8	$	146.3

Tax effect	(0.2)		(8.2)		(7.2)		(15.6)
Balance at October 31, 2021	$	(320.3)	$	13.1	$	(34.1)	$	(341.3)

Share Repurchases

In December 2011, the Company's Board of Directors authorized the 2012 Share Repurchase Program and through subsequent amendments, the most recent in March 2017, the total repurchase authorization was increased from $500.0 million to $1.0 billion of the Company's common stock. The program has no expiration date and may be discontinued at any time. Purchases under the 2012 Share Repurchase Program are subject to

a review of the circumstances in place at the time and may be made from time to time as permitted by securities laws and other legal requirements.

For the years ended October 31, 2021 and 2020, the Company share repurchases were as follow:


Years Ended October 31,	2021		2020
Number of shares	69,622		160,850
Average repurchase price per share	$	356.6	$	296.9
Total costs of shares repurchased (in millions)	$	24.8	$	47.8

At October 31, 2021, $334.8 million remained authorized for repurchase under the program.

Dividends

In fiscal 2021 and 2020, the Company paid a semiannual dividend of 3 cents per share: $1.5 million or 3 cents per share on February 9, 2021 to stockholders of record on January 22, 2021; $1.5 million or 3 cents per share on August 11, 2021 to stockholders of record on July 27, 2021; $1.5 million or 3 cents per share on February 10, 2020 to stockholders of record on January 23, 2020; $1.5 million or 3 cents per share on August 7, 2020 to stockholders of record on July 23, 2020.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Stock Plans

12 Months Ended

Oct. 31, 2021

Share-based Payment Arrangement [Abstract]

Stock Plans

2020 Long-Term Incentive Plan for Non-Employee Directors (2020 Directors' Plan)

In March 2020, we received stockholder approval of the 2020 Directors' Plan. The 2020 Directors' Plan authorizes either the Company's Board of Directors or a designated committee thereof composed of two or more Non-Employee Directors to grant to Non-Employee Directors equity awards for up to 50,000 shares of common stock, subject to adjustment for future stock splits, stock dividends, expirations, forfeitures and similar events.

The 2020 Directors' Plan provides for annual equity award grants to Non-Employee Directors on April 1st of each fiscal year which subsequently vest on the first anniversary of the date of grant. If a Non-Employee Director is appointed or elected after April 1, then they will receive a grant on the date of such appointment or election that is proportionally adjusted to reflect the number of months of actual service on the board during the first fiscal year of their election or appointment. The 2020 Directors' Plan also allows the Board of Directors to make discretionary grants to Non-Employee Directors.

Under the 2020 Directors' Plan, awards are made in the form of RSUs unless otherwise approved by the Board of Directors. RSUs entitle the recipient to receive shares of common stock, without any payment in cash or property. Legal ownership of the shares is not transferred until the unit vests and issued RSUs have no dividend or voting rights prior to vesting. Awards are made with a total target grant date value of $270,000, or $283,500 in the case of the Lead Director and $297,000 in the case of the Chairman of the Board.

Awards may also be made in the form of stock options or restricted stock. In the event of such awards, grants of stock options will have an exercise price equal to 100% of fair market value on the date of grant and expire no more than 10 years after the grant date. Awards of restricted stock provide the right to receive shares, subject to such purchase price requirements, restrictions on sale or transfer, or other conditions as approved by the Board of Directors. Restricted shares retain dividend and voting rights.

As of October 31, 2021, 37,853 shares remain available under the 2020 Directors' Plan for future grants.

2007 Long-Term Incentive Plan (2007 Plan)

In March 2007, we received stockholder approval of the 2007 Plan. The 2007 Plan was subsequently amended and restated, and granted stockholder approval in March 2009, March 2011, and March 2016.

The Third Amended and Restated 2007 Plan is designed to increase our stockholder value by attracting, retaining and motivating key employees and consultants who directly influence our profitability. The Third Amended and Restated 2007 Plan authorizes either our Board of Directors, or a designated committee thereof composed of two or more Non-Employee Directors, to grant to eligible individuals during the period ending December 31, 2026, up to 6,930,000 shares in the form of specified equity awards including stock options, restricted stock units and performance share awards, subject to adjustment for future stock splits, stock dividends, expirations, forfeitures and similar events.

During fiscal 2021, we granted stock options, restricted stock units, and performance share awards to employees under the Third Amended and Restated 2007 Plan. All stock options are granted at 100% of fair market value on the date of grant and expire no more than 10 years after the grant date. RSUs are nontransferable awards entitling the recipient to receive shares of common stock, without any payment in cash or property, in one or more installments at a future date or dates as determined by the Board of Directors or its authorized committee. For RSUs, legal ownership of the shares is not transferred to the employee until the unit vests, which is generally over a specified time period and RSUs have no dividend or voting rights prior to vesting. Performance share awards are nontransferable awards entitling the recipient to receive a variable number of shares of common stock, without any payment in cash or property, in one or more installments at a future date or dates as determined by the Board of Directors or its authorized committee. Legal ownership of the shares is not transferred to the recipient until the award vests, and the number of shares distributed is dependent upon the achievement of certain performance targets over a specified period of time.

As of October 31, 2021, 908,753 shares remained available under the Third Amended and Restated 2007 Plan for future grants. The amount of available shares includes shares which may be distributed under performance share awards.

Share-Based Compensation

Compensation expense and the related tax benefit recognized in our Consolidated Statements of Income for share-based awards, including the Employee Stock Purchase Plan, were as follows:


October 31,
(In millions)	2021		2020		2019
Selling, general and administrative expense	$	38.4	$	32.2	$	28.7
Cost of sales	3.9		4.0		4.7
Research and development expense	2.4		2.4		2.9
Total compensation expense	$	44.7	$	38.6	$	36.3
Related income tax benefit	$	5.6	$	4.8	$	5.1

Stock Options

The fair value of each stock option award granted is estimated on the date of grant using the Black-Scholes option valuation model and assumptions noted in the following table. The expected life of the awards is based on the observed and expected time to post-vesting forfeiture and/or exercise. Groups of employees that have similar historical exercise behavior are considered separately for valuation purposes. In determining the expected volatility, management considers implied volatility from publicly-traded options on our common stock at the date of grant, historical volatility and other factors. The risk-free interest rate is based on the continuous rates provided by the United States Treasury with a term equal to the expected life of the option. The dividend yield is based on the projected annual dividend payment per share, divided by the stock price at the date of grant.


Years Ended October 31,	2021		2020		2019
Expected life	4.0 years		4.4 years		4.4 years
Expected volatility	30.3	%	24.5	%	22.0	%
Risk-free interest rate	0.3	%	1.6	%	2.9	%
Dividend yield	0.02	%	0.02	%	0.02	%

The activity and status of our stock option plans are summarized below:


	Number of Shares	Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at October 31, 2020	1,103,507	$	213.53
Granted	109,440	$	345.74
Exercised	(235,478)	$	142.31
Forfeited or expired	(4,777)	$	327.62
Outstanding at October 31, 2021	972,692	$	245.09	6.22
Vested and expected to vest at October 31, 2021	939,788	$	243.15	6.16	$	163,310,445
Vested and exercisable at October 31, 2021	470,748	$	207.13	4.99	$	98,757,454

The weighted-average fair value of each option granted during fiscal 2021, estimated as of the grant date using the Black-Scholes option pricing model, for the 2007 Plan was $84.10. No options were granted under the 2020 Directors' Plan in fiscal 2021. The total intrinsic value of options exercised during the fiscal year ended October 31, 2021 was $64.7 million.

The weighted-average fair value of each option granted during fiscal 2020 and 2019, estimated as of the grant date using the Black-Scholes option pricing model, for the 2007 Plan was $70.45 and $60.71, respectively. The total intrinsic value of options exercised during fiscal 2020 and 2019 was $22.6 million and $40.1 million, respectively.

Stock options outstanding under our current plans have been granted at prices which are either equal to or above the market value of the common stock on the date of grant. Options granted under the 2007 Plan generally vest over a range of three to five years based on service conditions and expire no later than ten years after the grant date. Options granted under the 2020 Directors' Plan generally vest in one year and expire no later than ten years after the grant date. We generally recognize compensation expense ratably over the vesting period. However, Directors' options grants would have been expensed on the date of grant as the 2020 Directors' Plan did not contain a substantive future requisite service period. As of October 31, 2021, there was

$21.0 million of total unrecognized compensation cost related to nonvested options, which is expected to be recognized over a remaining weighted-average vesting period of 2.7 years.

Restricted Stock Units

RSUs granted under the 2007 Plan generally vest over three to five years. RSUs granted under the 2020 Directors' Plan vest in one year. The fair value of RSUs is estimated on the date of grant based on the market price of our common stock. We recognize compensation expense ratably over the vesting period. As of October 31, 2021, there was $63.1 million of total unrecognized compensation cost related to nonvested RSUs, which is expected to be recognized over a remaining weighted-average vesting period of 2.8 years.

The status of our non-vested RSUs is summarized below:


	Number of Shares	Weighted- Average Grant Date Fair Value Per Share
Non-vested RSUs at October 31, 2020	368,620	$	247.09
Granted	114,111	$	352.92
Vested and issued	(137,119)	$	222.42
Forfeited or expired	(28,277)	$	269.62
Non-vested RSUs at October 31, 2021	317,335	$	293.80

Performance Units

Performance units may be granted to selected key employees with vesting contingent upon meeting future reported earnings per share goals over a defined performance cycle, usually three years. Performance units, if earned, may be paid in cash or shares of common stock. We granted performance unit awards on December 8, 2020 under the 2007 Plan. The performance shares actually earned will range from zero to 200% of the target number of performance shares for performance periods ending in fiscal 2021 through fiscal 2024. Subject to limited exceptions set forth in the performance share plan, any shares earned will be distributed in the subsequent fiscal year after the performance period. The fair value of performance unit awards is estimated on the date of grant based on the current market price of our common stock and the estimate of probability of award achievement. This estimate is reviewed each fiscal quarter and adjustments are recorded if it is determined that the estimate of probability of award achievement has changed.

We recognize compensation expense ratably over the vesting period. As of October 31, 2021, there was $10.2 million of total unrecognized compensation cost related to non-vested performance units, which is expected to be recognized over a remaining weighted-average vesting period of 2.3 years.

Employee Stock Purchase Plan

On March 18, 2019, the Company received stockholder approval for the Employee Stock Purchase Plan (ESPP). The first offering period began on November 4, 2019 and offerings are generally made on a quarterly basis. The purpose of the ESPP is to provide eligible employees of the Company with the opportunity to acquire shares of common stock at 85% of the market price on the last business day of each offering period by means of accumulated payroll deductions. Payroll deductions will be limited to maximum of 15% of the employee’s eligible compensation, not to exceed $21.3 thousand in any one calendar year. The ESPP initially authorized the issuance of 1,000,000 shares of common stock. These shares will be made available from shares of common stock reacquired by the Company as Treasury Stock. During fiscal 2021 and 2020, we issued 17,575 and 11,641 shares to our employees under the ESPP, respectively. At October 31, 2021, the number of shares remaining available for future issuance under the ESPP was 970,784 shares. Total ESPP share-based compensation recognized during fiscal 2021 and 2020 was $1.0 million and $0.7 million, respectively.

Employee Benefits

12 Months Ended

Oct. 31, 2021

Retirement Benefits [Abstract]

Employee Benefits

Cooper's Retirement Income Plan

Cooper's Retirement Income Plan (Plan), a defined benefit plan, covers substantially all full-time United States employees. Cooper's contributions are designed to fund normal cost on a current basis and to fund the estimated prior service cost of benefit improvements. The unit credit actuarial cost method is used to determine the annual cost. Cooper pays the entire cost of the Plan and funds such costs as they accrue. Virtually all of the assets of the Plan are comprised of equities and participation in equity and fixed income funds.

The Company uses individual spot rates along the yield curve that correspond with the timing of each benefit payment to determine the service and interest costs of components of its net periodic benefit cost utilizing the correlation of projected cash outflows and corresponding spot rates on the yield curve.

The following table sets forth the Plan's benefit obligations and fair value of the Plan assets at October 31, 2021, 2020 and 2019 and the funded status of the Plan and net periodic pension costs for each of the years in the three-year periods ended October 31, 2021.

Retirement Income Plan


Years Ended October 31, (In millions)	2021		2020		2019
Change in benefit obligation
Benefit obligation, beginning of year	$	218.8	$	189.7	$	147.1
Service cost	17.2		13.9		10.1
Interest cost	4.4		5.2		6.1
Benefits paid	(11.5)		(10.0)		(10.2)

Actuarial loss	2.0		20.0		36.6
Benefit obligation, end of year	$	230.9	$	218.8	$	189.7
Change in plan assets
Fair value of plan assets, beginning of year	$	159.5	$	136.0	$	121.0
Actual return on plan assets	38.8		10.1		12.1
Employer contributions	12.7		23.4		13.1
Benefits paid	(11.5)		(10.0)		(10.2)
Fair value of plan assets, end of year	$	199.5	$	159.5	$	136.0
Funded status at end of year	$	(31.4)	$	(59.3)	$	(53.7)


Years Ended October 31, (In millions)	2021		2020		2019
Amounts recognized in the Consolidated Balance Sheets consist of:


Noncurrent liabilities	$	(31.4)	$	(59.3)	$	(53.7)
Net amount recognized at year end	$	(31.4)	$	(59.3)	$	(53.7)


Years Ended October 31, (In millions)	2021		2020		2019
Amounts recognized in accumulated other comprehensive income consist of:


Net loss	$	44.4	$	74.2	$	57.3
Accumulated other comprehensive income	$	44.4	$	74.2	$	57.3


Years Ended October 31, (In millions)	2021		2020		2019
Information for defined benefit plans with projected benefit obligation in excess of plan assets:
Projected benefit obligation	$	230.9	$	218.8	$	189.7
Fair value of plan assets	$	199.5	$	159.5	$	136.0


Years Ended October 31, (In millions)	2021		2020		2019
Information for defined benefit plans with accumulated benefit obligations in excess of plan assets:
Accumulated benefit obligation	$	207.6	$	195.8	$	170.8
Fair value of plan assets	$	199.5	$	159.5	$	136.0


Years Ended October 31, (In millions)	2021		2020		2019
Reconciliation of (prepaid) accrued pension cost:
(Prepaid)/Accrued pension cost at prior fiscal year end	$	(14.8)	$	(3.7)	$	2.2
Net periodic benefit cost	14.5		12.3		7.2
Contributions made during the year	(12.7)		(23.4)		(13.1)

(Prepaid)/Accrued pension cost at fiscal year end	$	(13.0)	$	(14.8)	$	(3.7)


Years Ended October 31, (In millions)	2021		2020		2019
Components of net periodic benefit cost and other amounts recognized in the Consolidated Statements of Income:
Net periodic benefit cost:
Service cost	$	17.2	$	13.9	$	10.1
Interest cost	4.4		5.2		6.1
Expected return on plan assets	(12.5)		(10.8)		(9.8)


Recognized actuarial loss	5.4		4.0		0.8
Net periodic pension cost	$	14.5	$	12.3	$	7.2


Years Ended October 31, (In millions)	2021		2020		2019
Other changes in plan assets and benefit obligations recognized in other comprehensive income:


Net (gain) loss	$	(24.4)	$	20.8	$	34.2


Amortizations of net gain	(5.4)		(4.0)		(0.8)



Total recognized in other comprehensive (income) loss	$	(29.8)	$	16.8	$	33.4
Total recognized in net periodic benefit cost and other comprehensive (income) loss	$	(15.2)	$	29.0	$	40.6


Years Ended October 31,	2021		2020		2019
Weighted-average assumptions used in computing the net periodic pension cost and projected benefit obligation at year end:
Discount rate for determining net periodic pension cost:
Projected Benefit Obligation	2.78	%	3.13	%	4.42	%
Service Cost	2.86	%	3.18	%	4.49	%
Interest Cost	2.07	%	2.78	%	4.22	%
Discount rate for determining benefit obligations at year end	2.76	%	2.78	%	3.13	%
Rate of compensation increase for determining expense	3.60	%	3.60	%	4.00	%
Rate of compensation increase for determining benefit obligations at year end	3.60	%	3.60	%	3.60	%
Expected rate of return on plan assets for determining net periodic pension cost	8.00	%	8.00	%	8.00	%
Expected rate of return on plan assets at year end	8.00	%	8.00	%	8.00	%
Measurement date for determining assets and benefit obligations at year end	10/31/2021		10/31/2020		10/31/2019

The discount rate enables us to state expected future cash flows at a present value on the measurement date. The discount rate used for the Plan is based primarily on the yields of a universe of high-quality corporate bonds rated AA or above, with durations corresponding to the expected durations of the benefit obligations. A change in the discount rate will cause the present value of benefit obligations to change in the opposite direction. If a discount rate of 2.78%, which is 0.35% lower than prior fiscal year, had been used, the projected benefit obligation would have been $230.2 million, and the accumulated benefit obligation would have been $207.0 million.

The expected rate of return on plan assets was determined based on a review of historical returns, both for this plan and for medium- to large-sized defined benefit pension funds with similar asset allocations. This review generated separate expected returns for each asset class listed below. These expected future returns were then blended based on this Plan's target asset allocation.

Reasons for Significant Liability Gains and Losses

The projected benefit obligation experienced a net loss of approximately $2.0 million during the year. This loss is primarily due to losses from assumption changes of approximately $0.7 million, and losses of approximately $1.3 million due to demographic experience. The key assumption changes were the decrease in the discount rate (loss of $0.7 million), a change in the mortality tables projection scale (loss of $0.5 million), and changes in assumptions for lump sum determination (gain of $0.5 million). The primary reasons for demographic losses were the net effect of retirement rates, termination rates, salary increases and other experience that was different from assumed.

Plan Assets

Weighted-average asset allocations at year end, by asset category are as follows:


Years Ended October 31,	2021		2020		2019
Asset category
Cash and cash equivalents	5.0	%	11.8	%	3.2	%

Equity mutual funds	62.8	%	57.7	%	63.7	%
Hedging Strategy Funds	4.7	%	4.3	%	4.9	%

Bond mutual funds	27.5	%	26.2	%	28.2	%
Total	100.0	%	100.0	%	100.0	%

The Plan invests in a diversified portfolio of assets intended to minimize risk of poor returns while maximizing expected portfolio returns. To achieve the long-term rate of return, plan assets will be invested in a mixture of instruments, including but not limited to, corporate common stock (may include the Company's stock), investment grade bond funds, cash, balanced funds, real estate funds, small or large cap equity funds and international equity funds. The allocation of assets will be determined by the investment manager and will typically include 50% to 70% equities with the remainder invested in fixed income, real estate, alternatives and cash. Presently, this diversified portfolio is expected to return roughly 8% in the long run.

As of the measurement date of October 31, 2021, the fair value measurement of plan assets is as follows:


(In millions)	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Asset category
Cash and cash equivalents	$	10.0	$	10.0	$	—	$	—

Equity mutual funds	125.3		125.3		—		—
Hedging Strategy Funds	9.4		9.4		—		—
Bond mutual funds	54.8		24.5		30.2		0.1
Total	$	199.5	$	169.2	$	30.2	$	0.1

The Plan has an established process for determining the fair value of plan assets. Fair value is based upon quoted market prices, as Level 1 inputs, where available. For investments in equity and bond mutual funds, and real estate funds, fair value is based on observable, Level 1 inputs, as price quotes are available and the fair values of these funds were not impacted by liquidity restrictions or the fund status. Level 2 assets are those where price quotes are not readily available and the fair value would be determined based on other observable inputs. Level 3 assets are those where price quotes are not readily available and the fair value would be determined based on unobservable inputs.

While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

Plan Cash Flows

Contributions

The Company contributions to the Plan were $12.7 million for fiscal 2021, $23.4 million for fiscal 2020 and, $13.1 million for fiscal 2019. The Company closely monitors the funded status of the Plan with respect to legislative and accounting rules. The Company does not expect to make a contribution to the Plan during fiscal 2022.

Estimated Future Benefit Payments


Years (In millions)
2022	$	10.7
2023	$	11.6
2024	$	12.8
2025	$	13.7
2026	$	14.4
2027-2031	$	79.6

Plan Soft Freeze

On June 18, 2019 the Board of Directors of the Company approved a soft freeze of the Plan effective August 1, 2019. The Plan was closed to employees hired on or after August 1, 2019, including former participants or employees rehired on or after August 1, 2019 and employees hired in connection with a stock or asset acquisition, merger or other similar transaction on or after August 1, 2019. Existing employees already covered by the Plan, continue to accrue their benefits.

Cooper's 401(k) Savings Plan

Cooper's 401(k) savings plan provides for the deferral of compensation as described in the Internal Revenue Code and is available to substantially all United States employees. Employees who participate in the 401(k) plan may elect to have up to 75% of their pre-tax salary or wages deferred and contributed to the trust established under the Plan. Cooper's contributions on account of participating employees, were $7.2 million, $6.8 million and $6.5 million for the years ended October 31, 2021, 2020 and 2019, respectively.

International Defined Benefit Plans

For its employees outside the United States, the Company also participates in country-specific defined contribution plans and government-sponsored retirement plans. The defined contribution plans are administered by third-party trustees and the Company is not directly responsible for providing benefits to participants of government-sponsored plans. The Company’s contributions to such plans are not significant individually or in the aggregate.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

+ Details

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Oct. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value MeasurementsAccounting standards define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value. An asset’s or liability’s level is based on the lowest level of input that is significant to the fair value measurement. Assets and liabilities carried at fair value are valued and disclosed in one of the following three levels of the valuation hierarchy: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions. At October 31, 2021 and October 31, 2020, the carrying value of cash and cash equivalents, accounts receivable, prepaid expense and other current assets, lines of credit, accounts payable and other current liabilities approximate fair value due to the short-term nature of such instruments and the ability to obtain financing on similar terms. The carrying value of the Company's revolving credit facility and term loans approximates fair value based on current market rates (Level 2). On April 6, 2020 the Company entered into six interest rate swap contracts which are used to hedge its exposure to changes in cash flows associated with its variable rate debt and are designated as derivatives in a cash flow hedge. The payment streams are based on a total notional amount of $1.5 billion at the inception of the contracts. The interest rate swap contracts had maturities of seven years or less. As of October 31, 2021, three of the six interest rate swap contracts have matured and the outstanding contracts have a total notional amount of $1.0 billion. The gain or loss on the derivatives is recorded as a component of accumulated other comprehensive income and subsequently reclassified into interest expense in the same period during which the hedged transaction affects earnings. The fair value of the interest rate swap contracts is measured on a recurring basis by netting the discounted future fixed cash payments and the discounted expected variable cash receipts. The variable cash receipts are based on the expectation of future interest rates (forward curves) derived from observable market interest rate curves. The interest rate swap contracts were categorized as Level 2 in the fair value hierarchy, as the inputs to the derivative pricing model are generally observable and do not contain a high level of subjectivity. Refer to Note 14. Financial Derivatives and Hedging for further information. The Company did not have any cross-currency swaps or foreign currency forward contracts as of October 31, 2021. The fair value of the Company's contingent consideration for which a liability is recorded is measured on a recurring basis as a Level 3 measurement, and the change in fair value is recognized in selling, general and administrative expense in the Consolidated Statements of Income. Refer to Note 3. Acquisitions and Assets Held for Sale for further information. Nonrecurring fair value measurements The Company uses fair value measures when determining assets and liabilities acquired in an acquisition as described in Note 3. Acquisitions and Assets Held for Sale, which are considered a Level 3 measurement.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Contingencies	12 Months Ended
Contingencies	Oct. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies Legal Proceedings The Company is involved in various lawsuits, claims and other legal matters from time to time that arise in the ordinary course of conducting business, including matters involving our products, intellectual property, supplier relationships, distributors, competitor relationships, employees and other matters. The Company does not believe that the ultimate resolution of these proceedings or claims pending against it could have a material adverse effect on its financial condition or results of operations. At each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal fees are expensed as incurred.

Business Segment Information

12 Months Ended

Oct. 31, 2021

Segment Reporting [Abstract]

Business Segment Information

The Company discloses information about its operating segments, which were established based on the way that management organizes segments within the Company for making operating decisions and assessing financial performance. The Company's two operating segments are described below.

•CooperVision. Competes in the worldwide contact lens market by developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics. CooperVision designs its products to solve vision challenges such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues, with a broad collection of spherical, toric and multifocal contact lenses.

•CooperSurgical. Competes in the general health care market with a focus on advancing the health of women, babies and families through a diversified portfolio of products and services focusing on women's health and fertility.

Cooper uses operating income, as presented in our financial reports, as the primary measure of segment profitability. We do not allocate costs from corporate functions to segment operating income. Items below operating income are not considered when measuring the profitability of a segment. We use the same accounting policies to generate segment results as we do for our consolidated results.

Total net sales include sales to customers as reported in our Consolidated Statements of Income and sales between geographic areas that are priced at terms that allow for a reasonable profit for the seller. Operating income (loss) is total net sales less cost of sales, selling, general and administrative expenses, research and development expenses, amortization and intangible impairments. Corporate operating loss is principally corporate headquarters expense. Interest expense, and other income and expenses are not allocated to individual segments.

No customer accounted for 10% or more of our consolidated net revenue in the fiscal 2021, 2020 and 2019.

Identifiable assets are those used in continuing operations except cash and cash equivalents, which we include as corporate assets. Long-lived assets are net property, plant and equipment.

The following table presents a summary of our business segment net sales:


(In millions)	2021		2020		2019
CooperVision net sales by category:
Toric lens	$	697.5	$	598.2	$	620.0
Multifocal lens	238.6		197.0		202.9
Single-use sphere lens	616.3		529.0		568.2
Non single-use sphere, other	599.6		518.8		581.8
Total CooperVision net sales	2,152.0		1,843.0		1,972.9
CooperSurgical net sales by category:
Office and surgical products	451.3		358.8		422.4
Fertility	319.2		229.1		258.1
Total CooperSurgical net sales	770.5		587.9		680.5
Total net sales	$	2,922.5	$	2,430.9	$	2,653.4

Information by business segment for each of the years in the three-year period ended October 31, 2021, follows:


(In millions)	CooperVision		CooperSurgical		Corporate		Consolidated
2021
Net sales	$	2,152.0	$	770.5	$	—	$	2,922.5
Operating income (loss)	$	481.3	$	71.8	$	(47.3)	$	505.8
Interest expense							23.1
Other (income), net							(8.8)
Income before income taxes							$	491.5
Identifiable assets	$	6,965.9	$	2,395.6	$	244.7	$	9,606.2
Depreciation expense	$	148.3	$	14.9	$	—	$	163.2
Amortization expense	$	35.7	$	110.4	$	—	$	146.1
Capital expenditures	$	190.0	$	24.4	$	—	$	214.4
2020
Net sales	$	1,843.0	$	587.9	$	—	$	2,430.9
Operating income (loss)	$	375.7	$	(14.7)	$	(49.2)	$	311.8
Interest expense							36.8
Other expense, net							8.5
Income before income taxes							$	266.5
Identifiable assets	$	4,236.3	$	2,293.8	$	207.4	$	6,737.5
Depreciation expense	$	138.2	$	11.7	$	—	$	149.9
Amortization expense	$	32.4	$	104.8	$	—	$	137.2
Capital expenditures	$	260.3	$	50.1	$	—	$	310.4
2019
Net sales	$	1,972.9	$	680.5	$	—	$	2,653.4
Operating income (loss)	$	506.4	$	87.9	$	(47.6)	$	546.7
Interest expense							68.0
Other expense, net							1.3
Income before income taxes							$	477.4
Identifiable assets	$	3,911.6	$	2,189.8	$	173.1	$	6,274.5
Depreciation expense	$	125.8	$	9.0	$	0.2	$	135.0
Amortization expense	$	40.9	$	104.9	$	—	$	145.8
Capital expenditures	$	259.0	$	33.1	$	—	$	292.1

Information by geographical area by country of domicile for each of the years in the three-year period ended October 31, 2021, follows:


(In millions)	United States		Europe		Rest of World, Other Eliminations & Corporate		Consolidated
2021
Net sales to unaffiliated customers	$	1,339.2	$	957.9	$	625.4	$	2,922.5
Sales between geographic areas	494.9		815.1		(1,310.0)		—
Net sales	$	1,834.1	$	1,773.0	$	(684.6)	$	2,922.5
Operating (loss) income	$	(26.8)	$	416.2	$	116.4	$	505.8
Long-lived assets	$	737.5	$	377.2	$	232.9	$	1,347.6
2020
Net sales to unaffiliated customers	$	1,103.6	$	789.8	$	537.5	$	2,430.9
Sales between geographic areas	391.7		327.1		(718.8)		—
Net sales	$	1,495.3	$	1,116.9	$	(181.3)	$	2,430.9
Operating (loss) income	$	(14.5)	$	21.9	$	304.4	$	311.8
Long-lived assets	$	721.3	$	363.0	$	197.6	$	1,281.9
2019
Net sales to unaffiliated customers	$	1,211.8	$	854.8	$	586.8	$	2,653.4
Sales between geographic areas	650.7		300.8		(951.5)		—
Net sales	$	1,862.5	$	1,155.6	$	(364.7)	$	2,653.4
Operating income	$	83.2	$	29.3	$	434.2	$	546.7
Long-lived assets	$	626.5	$	358.8	$	146.8	$	1,132.1

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Financial Derivatives and Hedging

12 Months Ended

Oct. 31, 2021

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Financial Derivatives and Hedging

As part of the Company’s overall risk management practices the Company enters into financial derivatives, interest rate swaps designated as cash flow hedges, to hedge the Company's exposure to changes in cash flows associated with its variable rate debt.

The Company records all derivatives on its Consolidated Balance Sheets at fair value. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting, and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. All of the Company's derivatives have satisfied the criteria necessary to apply hedge accounting.

The gain or loss on derivative instruments designated and qualifying for cash flow hedge accounting is deferred in other comprehensive income. The changes in fair value for all trades that are not designated for hedge accounting are recognized in current period earnings. Deferred gains or losses from designated cash flow hedges are reclassified into earnings in the period that the hedged interest expense affects earnings. The effectiveness of cash flow hedges is assessed at inception and quarterly thereafter. The Company does not offset fair value amounts recognized for derivative instruments in its Consolidated Balance Sheets for presentation purposes.

Credit risk related to derivative transactions reflects the risk that a party to the transaction could fail to meet its obligation under the derivative contracts. Therefore, the Company’s exposure to the counterparty’s credit risk is generally limited to the amounts, if any, by which the counterparty’s obligations to the Company exceed the Company’s obligations to the counterparty. The Company’s policy is to enter into contracts only with financial institutions which meet certain minimum credit ratings to help mitigate counterparty credit risk.

As of October 31, 2021, the Company had the following outstanding derivatives designated as hedging instruments:


(In millions, except for number of instruments)	Number of Instruments	Notional Value
Interest Rate Swap Contracts	3	$	1,000

These contracts have remaining maturities of six years or less.

The pre-tax impact of gain on derivatives designated for hedge accounting recognized in other comprehensive income (loss) was $17.2 million ($13.1 million, net of tax) as of October 31, 2021. The pre-tax impact of loss on derivatives designated for hedge accounting recognized in other comprehensive income (loss) was $17.1 million ($13.0 million, net of tax) as of October 31, 2020.

The following table summarizes the fair values of derivative instruments as of the periods indicated and the line items in the accompanying Consolidated Balance Sheets where the instruments are recorded:


	Derivative Assets
(In millions)			October 31, 2021		October 31, 2020
Derivatives designated as cash flow hedges		Balance sheet location
Interest rate swap contracts		Other current assets	$	—	$	—
Interest rate swap contracts		Other non-current assets	17.2		—
			$	17.2	$	—


	Derivative Liabilities
(In millions)			October 31, 2021		October 31, 2020
Derivatives designated as cash flow hedges		Balance sheet location
Interest rate swap contracts		Other current liabilities	$	—	$	0.6
Interest rate swap contracts		Other non-current liabilities	—		16.5
			$	—	$	17.1

The following table summarizes the amounts recognized with respect to our derivative instruments within the accompanying Consolidated Statements of Income:


Periods Ended October 31,
(In millions)		2021		2020		2019
Derivatives designated as cash flow hedges	Location of Loss Recognized on Derivatives
Interest rate swap contracts	Interest expense	$	8.0	$	3.7	$	—

The Company expects that $5.1 million recorded as a component of accumulated other comprehensive income (loss) will be realized in the Consolidated Statements of Income over the next twelve months and the amount will vary depending on prevailing interest rates.

The following table details the changes in accumulated other comprehensive income:


(In millions)	Amount
Balance as of October 31, 2019	$	—
Amount recognized in other comprehensive income on interest rate swap contracts, gross ($(15.8), net of tax)	(20.8)
Amount reclassified from other comprehensive income into earnings, gross ($2.8, net of tax)	3.7
Balance loss as of October 31, 2020	$	(17.1)
Amount recognized in other comprehensive income on interest rate swap contracts, gross ($20.0, net of tax)	26.3
Amount reclassified from other comprehensive income into earnings, gross ($6.1, net of tax)	8.0
Balance gain as of October 31, 2021	$	17.2

Subsequent Events	12 Months Ended
Subsequent Events	Oct. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Term Loan Agreement on November 2, 2021 On November 2, 2021, subsequent to the fiscal year ended October 31, 2021, the Company entered into a 364-day, $840.0 million, term loan agreement by and among the Company, the lenders party thereto and The Bank of Nova Scotia, as administrative agent (the 2021 Term Loan Agreement), which matures on November 1, 2022. The Company used part of the funds to partially repay outstanding borrowings under the 2020 Revolving Credit Facility and for general corporate purposes. Amounts outstanding under the 2021 Term Loan Agreement will bear interest, at the Company’s option, at either the alternate base rate, or the adjusted LIBO rate (each as defined in the 2021 Term Loan Agreement), plus, in the case of adjusted LIBO rate loans, an applicable rate of 60 basis points. The 2021 Term Loan Agreement contains customary restrictive covenants, as well as financial covenants that require the Company to maintain a certain total leverage ratio and interest coverage ratio, each as defined in the 2021 Term Loan Agreement, consistent with the 2020 Credit Agreement. See Note 5. Debt for additional information. Generate Life Sciences Acquisition On November 6, 2021, subsequent to the fiscal year ended October 31, 2021, CooperSurgical entered into an Agreement and Plan of Merger (the “Merger Agreement”) to acquire Generate Life Sciences, a privately held leading provider of donor egg and sperm for fertility treatments, fertility cryopreservation services and newborn stem cell (cord blood and cord tissue) storage. The aggregate consideration is $1.605 billion in cash, subject to adjustment as set forth in the Merger Agreement. The transaction is anticipated to close in the first quarter of fiscal 2022 and is subject to customary closing conditions, including regulatory approval. This acquisition is a strong strategic fit for CooperSurgical as it allows the Company to better serve fertility clinics and Obstetricians/Gynecologists (OB/GYN) with a more extensive suite of products and services.

Schedule II

12 Months Ended

Oct. 31, 2021

SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]

Schedule II

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

VALUATION AND QUALIFYING ACCOUNTS

Three Years Ended October 31, 2021


(In millions)	Balance Beginning of Year		Additions Charged to Costs and Expenses		(Deductions) Recoveries/ Other (1)		Balance at End of Year
Allowance for doubtful accounts:
Year Ended October 31, 2021	$	10.2	$	0.7	$	(1.7)	$	9.2
Year Ended October 31, 2020	$	16.4	$	3.6	$	(9.8)	$	10.2
Year Ended October 31, 2019	$	19.0	$	1.6	$	(4.2)	$	16.4

(1) Consists of additions representing allowances and recoveries, less deductions representing receivables written off as uncollectible.


(In millions)	Balance Beginning of Year	Additions	Reductions/ Charges	Balance at End of Year
Deferred income tax valuation allowance:
Year Ended October 31, 2021	45.3	8.8	(2.3)	51.8
Year Ended October 31, 2020	41.5	5.9	(2.1)	45.3
Year Ended October 31, 2019	39.1	3.9	(1.5)	41.5

Accounting Policies (Policies)	12 Months Ended
Accounting Policies (Policies)	Oct. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Estimates	Estimates The World Health Organization categorized the Coronavirus disease 2019 (COVID-19) as a pandemic. The COVID-19 pandemic has caused a severe global health crisis, along with economic and societal disruptions and uncertainties, which have negatively impacted business and healthcare activity globally. As a result of healthcare systems responding to the demands of managing the pandemic, governments around the world imposing measures designed to reduce the transmission of the COVID-19 virus, and individuals responding to the concerns of contracting the COVID-19 virus, many optical practitioners & retailers, hospitals, medical offices and fertility clinics closed their facilities, restricted access, or delayed or canceled patient visits, exams and elective medical procedures, and many customers that have reopened are experiencing reduced patient visits. These factors have had, and in the future may have, an adverse effect on our sales, operating results and cash flows. The preparation of Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of net sales and expenses during the reporting period. Actual results could differ from those estimates particularly as it relates to estimates reliant on forecasts and other assumptions reasonably available to the Company and the uncertain future impacts of the COVID-19 pandemic and related economic disruptions. The extent to which the COVID-19 pandemic and related economic disruptions impact our business and financial results will depend on future developments including, but not limited to, the continued spread, duration and severity of the COVID-19 pandemic; the occurrence, spread, duration and severity of any subsequent wave or waves of outbreaks, including the emergence and spread of variants of the COVID-19 virus; the actions taken by the U.S. and foreign governments to contain the COVID-19 pandemic, address its impact or respond to the reduction in global and local economic activity; the occurrence, duration and severity of a global, regional or national recession, depression or other sustained adverse market event; the impact of the developments described above on our customers and suppliers; and how quickly and to what extent normal economic and operating conditions can resume. The accounting matters assessed included, but were not limited to: •allowance for doubtful accounts and credit losses •the carrying value of inventory •the carrying value of goodwill and other long-lived assets There was not a material impact to the above estimates in the Company’s Consolidated Financial Statements for fiscal 2021. The Company continually monitors and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material changes to the estimates and material impacts to the Company’s Consolidated Financial Statements in future reporting periods. We believe that the accounting policies and estimates employed are appropriate and resulting balances are reasonable; however, actual results could differ from the original estimates, requiring adjustment to these balances in future periods.
Basis of accounting	Management's significant accounting policies include estimates and judgments which are an integral part of financial statements prepared in accordance with accounting principles generally accepted in the United States (GAAP). We believe that the accounting policies described in this section address the more significant policies utilized by management when preparing our consolidated financial statements in accordance with GAAP.
Revenue recognition	Revenue recognition Net Sales The Company sells its products principally to a limited number of distributors, group purchasing organizations, eye care or health care professionals including independent practices, corporate retailers, hospitals and clinics or authorized resellers (collectively, its Customers). These Customers subsequently resell the Company’s products to eye care or health care providers and patients. In addition to product supply and distribution agreements with Customers, the Company enters into arrangements with health care providers and payors that provide for government-mandated and/or privately negotiated rebates, chargebacks and discounts with respect to the purchase of the Company’s products. The Company considers customer purchase orders, which in some cases are governed by master sales agreements, to be contracts with a customer. In situations where sales are to a distributor, the Company has concluded that its contracts are with the distributor. As part of its consideration of the contract, the Company evaluates certain factors including the customer’s ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations. Revenues from product sales are recognized when the Customer obtains control of the Company’s product, which occurs at a point in time, typically upon shipment or delivery to the Customer. When the Company performs shipping and handling activities after the transfer of control to the Customer (e.g., when control transfers prior to delivery), they are considered as fulfillment activities, and accordingly, the costs are accrued for when the related revenue is recognized. Taxes collected from Customers relating to product sales and remitted to governmental authorities are excluded from revenues. The Company does not have any revenue recognized on payment expected to be received more than one year after the transfer of control of the products. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that the Company would have recognized is one year or less. See Note 13. Business Segment Information for disaggregation of revenue. Reserves for Variable Consideration Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from discounts, returns, chargebacks, rebates and other allowances that are offered within contracts between the Company and its Customers, health care providers, payors and other indirect customers relating to the Company’s sales of its products. These reserves are based on the amounts earned or to be claimed on the related sales and are classified primarily in current liabilities. Variable consideration is estimated based on the most likely amount or expected value approach, depending on which method the Company expects to better predict the amount of consideration to which it will be entitled. Once the Company elects one of the methods to estimate variable consideration for a particular type of performance obligation, the Company applies that method consistently. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known. Trade Discounts and Allowances The Company generally provides Customers with discounts, which include incentive fees that are stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company receives sales order management, data and distribution services from certain Customers. To the extent the services received are distinct from the Company’s sale of products to the Customer and have readily determinable fair value, these payments are classified in selling, general and administrative expenses in our Consolidated Statements of Income. Product Returns Consistent with industry practice, the Company generally offers Customers a limited right of return for a product that has been purchased from the Company. The Company estimates the amount of its product sales that may be returned by its Customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. There is inherent judgment in estimating future refunds as they are susceptible to factors outside of our influence. However, we have significant experience in estimating the amount of refunds, based primarily on historical data. Our refund liability for product returns was $13.7 million and $10.0 million at October 31, 2021 and 2020, respectively, which is included in Accrued Liabilities on our Consolidated Balance Sheets and represents the expected value of the aggregate refunds that will be due to our customers. Rebates and Chargebacks Rebates are estimated based on contractual terms, historical experience, customer mix, trend analysis and projected market conditions in the various markets served. Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list wholesale prices charged to the Company’s direct customers. For certain office and surgical products in CooperSurgical, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers. CooperSurgical rebates are predominately related to the Medicaid rebate provision that is estimated based upon contractual terms, historical experience, and trend analysis. Contract balances The timing of billing and revenue recognition primarily occurs simultaneously. The Company does not have material contract assets or liabilities.
Leases	Leases - We consider an arrangement a lease if the arrangement transfers the right to control the use of an identified asset in exchange for consideration. We have operating leases, but do not have material financing leases. Lease right-of-use assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make payments arising from the lease agreement. These assets and liabilities are recognized at the commencement of the lease based upon the present value of the future minimum lease payments over the lease term. The lease term reflects the noncancellable period of the lease together with periods covered by an option to extend or terminate the lease when management is reasonably certain that it will exercise such option. Changes in the lease term assumption could impact the right-of-use assets and lease liabilities recognized on the Consolidated Balance Sheets. As our leases typically do not contain a readily determinable implicit rate, we determine the present value of the lease liability using our incremental borrowing rate at the lease commencement date based on the lease term on a collateralized basis.
Net realizable value of inventory	Net realizable value of inventory - In assessing the value of inventories, we make estimates and judgments regarding aging of inventories and other relevant issues potentially affecting the salable condition of products and estimated prices at which those products will sell. On an ongoing basis, we review the carrying value of our inventory, measuring number of months on hand and other indications of salability. We reduce the value of inventory if there are indications that the carrying value is greater than net realizable value, resulting in a new, lower-cost basis for that inventory. Subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis. While estimates are involved, historically, obsolescence has not been a significant factor due to long product dating and lengthy product life cycles. Inventories are stated at the lower of cost or net realizable value. Cost is computed using standard cost that approximates actual cost, on a first-in, first-out basis.
Valuation of goodwill	Valuation of goodwill - We evaluate goodwill for impairment annually during the fiscal third quarter and when an event occurs or circumstances change such that it is reasonably possible that impairment may exist. We account for goodwill and evaluate our goodwill balances and test them for impairment in accordance with related accounting standards. We performed our annual impairment test in our third quarter of fiscal 2021 and 2020, and our analysis indicated that we had no impairment of goodwill in our reporting units.Goodwill impairment analysis and measurement is a process that requires significant judgment. If our common stock price trades below book value per share, there are changes in market conditions or a future downturn in our business, or a future goodwill impairment test indicates an impairment of our goodwill, we may have to recognize a non-cash impairment of goodwill that could be material and could adversely affect our results of operations in the period recognized and also adversely affect our total assets and stockholders' equity. We test goodwill impairment in accordance with ASU 2017-04, Intangibles - Goodwill and other (Topic 350): Simplifying the Test for Goodwill Impairment. We perform a qualitative assessment to test each reporting unit's goodwill for impairment. Qualitative factors considered in this assessment include industry and market considerations, overall financial performance and other relevant events and factors affecting each reporting unit. Based on our qualitative assessment, if we determine that the fair value of a reporting unit is more likely than not to be less than its carrying amount, the fair value of a reporting unit will be compared with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value of the reporting unit. A reporting unit is the level of reporting at which goodwill is tested for impairment.
Business combinations	Business combinations - We routinely consummate business combinations. Results of operations for acquired companies are included in our consolidated results of operations from the date of acquisition. We recognize separately from goodwill, the identifiable assets acquired, including acquired in-process research and development, the liabilities assumed, and any noncontrolling interest in the acquiree at the acquisition date fair values as defined by accounting standards related to fair value measurements. Key assumptions routinely utilized in allocation of purchase price to intangible assets include projected financial information such as revenue projections for companies acquired. As of the acquisition date, goodwill is measured as the excess of consideration given, over the net of the acquisition date fair values of the identifiable assets acquired and the liabilities assumed. Direct acquisition costs are expensed as incurred.
Income taxes	Income taxes - We account for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and for tax losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.As part of the process of preparing our consolidated financial statements, we must estimate our income tax expense for each of the jurisdictions in which we operate. This process requires significant management judgments and involves estimating our current tax exposures in each jurisdiction including the impact, if any, of additional taxes resulting from tax examinations as well as judging the recoverability of deferred tax assets. To the extent recovery of deferred tax assets is not likely based on our estimation of future taxable income in each jurisdiction, a valuation allowance is established. Tax exposures can involve complex issues and may require an extended period to resolve. Frequent changes in tax laws in each jurisdiction complicate future estimates. To determine the tax rate, we use the full-year income and the related income tax expense in each jurisdiction. We update the estimated effective tax rate for the effect of significant unusual items as they are identified. Changes in the geographic mix or estimated level of annual pre-tax income can affect the overall effective tax rate, and such changes could be material.We file income tax returns in all jurisdictions in which we operate. We record a liability for uncertain tax positions taken or expected to be taken in income tax returns that we have determined are not more-likely-than-not realizable. Our financial statements reflect expected future tax consequences of such positions presuming the taxing authorities' full knowledge of the position and all relevant facts. These tax reserves have been established based on management's assessment as to the potential exposure attributable to our uncertain tax positions as well as interest and penalties attributable to these uncertain tax positions. All tax reserves are analyzed quarterly and adjustments are made as events occur that result in changes in judgment
Share-based Compensation	Share-Based Compensation - We grant various share-based compensation awards, including stock options, performance unit shares, restricted stock and restricted stock units. Under fair value recognition provisions, share-based compensation expense is measured at the grant date based on the fair value of the award and is recognized as expense over the vesting period. Determining the fair value of share-based awards at the grant date requires judgment, including estimating Cooper's stock price volatility, employee exercise behaviors and related employee forfeiture rates. The expected life of the share-based awards is based on the observed and expected time to post-vesting forfeiture and/or exercise. Groups of employees that have similar historical exercise behavior are considered separately for valuation purposes. In determining the expected volatility, management considers implied volatility from publicly-traded options on Cooper's common stock at the date of grant, historical volatility and other factors. The risk-free interest rate is based on the continuous rates provided by the United States Treasury with a term equal to the expected life of the award. The dividend yield is based on the projected annual dividend payment per share, divided by the stock price at the date of grant. As share-based compensation expense recognized in our Consolidated Statements of Income is based on awards ultimately expected to vest, the amount of expense has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant, based on historical experience, and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. If factors change and we employ different assumptions in the application of the fair value recognition provisions, the compensation expense that we record in future periods may differ significantly from what we have recorded in the current period.
Accounting Pronouncements Recently Adopted and Accounting Pronouncements Issued Not Yet Adopted	Accounting Pronouncements Recently Adopted In January 2020, the Financial Accounting Standards Board (FASB) issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)—Clarifying the Interactions between Topic 321, Topic 323, and Topic 815. This guidance addresses accounting for the transition into and out of the equity method and provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. This standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2020. Early adoption is permitted. The Company early adopted this guidance in the second quarter of fiscal 2021, and it did not have a material impact on our Consolidated Financial Statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments and subsequent amendments to the initial guidance: ASU 2018-19 Codification Improvements to Topic 326, Financial Instruments-Credit Losses, ASU 2019-04 Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, ASU 2019-05 Financial Instruments-Credit Losses, ASU 2019-11 Codification Improvements to Topic 326, Financial Instruments—Credit Losses, ASU 2020-02 Financial Instruments—Credit Losses (Topic 326) and Leases (Topic 842) and ASU 2020-03 Codification Improvements to Financial Instruments (collectively, “Topic 326”). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. Topic 326 is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2019. The Company adopted this guidance in the first quarter of fiscal 2021 on a modified retrospective basis, and the most notable impact was related to the assessment of the adequacy of its allowance for doubtful accounts on trade accounts receivable and the recognition of credit losses. The Company recorded a cumulative-effect adjustment of $1.4 million to the Consolidated Balance Sheets on November 1, 2020. In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606. This guidance amended Topic 808 and Topic 606 to clarify that transactions in a collaborative arrangement should be accounted for under Topic 606 when the counterparty is a customer for a distinct good or service (i.e., unit of account). The amendments preclude an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. This guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2019. The Company adopted this guidance on November 1, 2020, and it did not have a material impact on our Consolidated Financial Statements. Accounting Pronouncements Issued Not Yet Adopted In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. This guidance removes certain exceptions to the general principles in Topic 740 and enhances and simplifies various aspects of the income tax accounting guidance, including requirements such as tax basis step-up in goodwill obtained in a transaction that is not a business combination, ownership changes in investments, and interim-period accounting for enacted changes in tax law. This standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2020. Early adoption is permitted. We are currently evaluating the impact of ASU 2019-12 on our Consolidated Financial Statements, which is effective for the Company in our fiscal year and interim periods beginning on November 1, 2021. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting and subsequent amendment to the initial guidance: ASU 2021-01, Reference Rate Reform (Topic 848): Scope (collectively, “Topic 848”). Topic 848 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The guidance generally can be applied from March 12, 2020 through December 31, 2022. We are currently assessing the impacts of the practical expedients provided in Topic 848 and which, if any, we will adopt. In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). This update amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity's own equity and improves and amends the related EPS guidance for both Subtopics. This standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2021, which means it will be effective for our fiscal year beginning November 1, 2022. Early adoption is permitted but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. We are currently evaluating the impact of ASU 2020-06 on our Consolidated Financial Statements. In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This update requires that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. This standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2022 and should be applied prospectively to business combinations occurring on or after the effective date of the standard. Early adoption is permitted, including adoption in an interim period. We are currently evaluating the impact of ASU 2021-08 on our Consolidated Financial Statements. In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. This update requires annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. This standard is effective for fiscal years beginning after December 15, 2021 and should be applied either prospectively or retrospectively. Early adoption is permitted. We are currently evaluating the impact of ASU 2021-10 on our Consolidated Financial Statements. No other recently issued accounting pronouncements had or are expected to have a material impact on our Consolidated Financial Statements.
Consolidation	Consolidation The financial statements in this report include the accounts of all of Cooper's consolidated entities. All significant intercompany transactions and balances are eliminated on consolidation.
Foreign Currency Translation	Foreign Currency Translation Most of our operations outside the United States use their local currency as their functional currency. We translate these assets and liabilities into United States dollars at year-end exchange rates. We translate income and expense accounts at average rates for each month. We record gains and losses from the translation of financial statements in foreign currencies into United States dollars in other comprehensive income. We record gains and losses from changes in exchange rates on transactions denominated in currencies other than each reporting location's functional currency in net income for each period.
Litigation	LitigationWe are subject to various legal proceedings, claims, litigation, investigations and contingencies arising out of the ordinary course of business. If we believe the likelihood of an adverse legal outcome is probable and the amount is estimable, we accrue a liability in accordance with accounting guidance for contingencies. We consult with legal counsel on matters related to litigation and seek input both within and outside the Company.
Long-lived Assets	Long-lived Assets We review long-lived assets held and used, intangible assets with finite useful lives and assets held for sale for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If an evaluation of recoverability is required, the estimated undiscounted future cash flows associated with the asset group are compared to the asset group's carrying amount to determine if a write-down is required. If the undiscounted cash flows are less than the carrying amount, an impairment loss is recorded to the extent that the carrying amount exceeds the fair value. If management has committed to a plan to dispose of long-lived assets, the assets to be disposed of are reported at the lower of carrying amount or fair value less estimated costs to sell.
Property, Plant and Equipment	CooperVision provides optometric practices with in-office lenses used in marketing programs to facilitate efficient and convenient fitting of contact lenses by practitioners. Such lens fitting sets generally consist of a physical binder or rack to store contact lenses and an array of lenses. We record the costs associated with the original fitting set to other long-term assets on our Consolidated Balance Sheets. We amortize such costs over their estimated useful lives to selling, general and administrative expense on our Consolidated Statements of Income. We also expense the cost for lenses provided to practitioners as replenishment for fitting sets in the period shipped to selling, general and administrative expense on our Consolidated Statements of Income.Property, plant and equipment are stated at cost. We compute depreciation using the straight-line method in amounts sufficient to write off depreciable assets over their estimated useful lives. We amortize leasehold improvements over their estimated useful lives or the period of the related lease, whichever is shorter. We depreciate buildings over 30 to 40 years and machinery and equipment over 3 to 15 years. We expense costs for maintenance and repairs and capitalize major replacements, renewals and improvements. We eliminate the cost and accumulated depreciation of depreciable assets retired or otherwise disposed of from the asset and accumulated depreciation accounts and reflect any gains or losses in operations for the period.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term, highly liquid investments purchased with maturities of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value.
Earnings Per Share	Earnings Per Share We determine basic earnings per share (EPS) by using the weighted average number of shares outstanding. We determine diluted EPS by increasing the weighted average number of shares outstanding in the denominator by the number of outstanding dilutive equity awards using the treasury stock method.
Treasury Stock	Treasury Stock We record treasury stock purchases under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock.

Accounting Policies (Tables)

12 Months Ended

Oct. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of inventory

Inventories


October 31, (In millions)	2021		2020
Raw materials	$	137.7	$	151.0
Work-in-process	14.0		12.4
Finished goods	433.9		407.0
	$	585.6	$	570.4

Schedule of property, plant and equipment

Property, Plant and Equipment


October 31, (In millions)	2021		2020
Land and improvements	$	20.3	$	19.9
Buildings and improvements	388.0		356.1
Machinery and equipment	1,863.6		1,764.9
Construction in progress	383.8		333.9
Property, plant and equipment, at cost	$	2,655.7	$	2,474.8
Less: Accumulated depreciation	1,308.1		1,192.9
	$	1,347.6	$	1,281.9

Leases (Tables)

12 Months Ended

Oct. 31, 2021

Leases [Abstract]

Leases on the Consolidated Condensed Balance Sheet

The following table presents information about leases on the Consolidated Balance Sheets:


October 31, (In millions)	2021			2020
Operating Leases
Operating lease right-of-use assets	$	257.0		$	260.2

Operating lease liabilities, current	35.7			33.3
Operating lease liabilities, non-current	231.7			236.8
Total operating lease liabilities	$	267.4		$	270.1

Weighted average remaining lease term (in years)	10.6			11.3
Weighted average discount rate	3		%	3		%

Schedule of lease cost

The following table presents information about lease expense, which is included in selling, general and administrative expenses in the Consolidated Statements of Income:


(In millions)	2021		2020
Operating lease expense	$	44.1	$	41.2
Short-term lease expense	0.9		4.4
Variable lease expense	$	0.4	$	1.8

The following table presents supplemental cash flow information about the Company’s leases:


(In millions)	2021		2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	37.4	$	40.6
Operating lease right-of-use assets obtained in exchange for lease obligations	$	26.5	$	17.7

Minimum rental payments required under operating leases

The minimum rental payments required under operating leases that have initial or remaining noncancellable lease terms in excess of one year as of October 31, 2021 are:


(In millions)
2022	$	42.5
2023	37.3
2024	31.9
2025	30.2
2026	29.4
Thereafter	146.3
Total lease payments	$	317.6
Less: interest	50.2
Present value of lease liabilities	$	267.4

Acquisitions and Assets Held for Sale (Tables)

12 Months Ended

Oct. 31, 2021

Business Combination and Asset Acquisition [Abstract]

Total purchase consideration for business and asset acquisitions

The following is a summary of the allocation of the total purchase consideration for business and asset acquisitions that the Company completed during fiscal 2021, 2020, and 2019:


(In millions)	2021		2020		2019
Technology	$	178.6	$	—	$	12.3
In-Process Research & Development (IPR&D)	20.0		—		—
Customer relationships	7.5		11.4		7.5
Trademarks	1.3		5.1		10.2
Other	0.6		3.9		0.1
Total identifiable intangible assets	$	208.0	$	20.4	$	30.1

Goodwill	91.6		15.3		29.8
Net tangible (liabilities) assets	(10.8)		(0.3)		7.3
Fair value of contingent consideration	(39.1)		—		—
Total closing purchase price	$	249.7	$	35.4	$	67.2

Contingent consideration reconciliation

The following table provides a reconciliation of the beginning and ending balances of contingent consideration:


(In millions)	2021		2020
Beginning balance	$	—	$	—
Purchase price contingent consideration	31.3		—
Payments	—		—
Change in fair value	66.1		—
Ending balance	$	97.4	$	—

Carrying amounts of the assets and liabilities held for sale

Included in the Company's Consolidated Balance Sheets as of October 31,2021 are the following carrying amounts of the assets and liabilities held for sale:


(In millions)	October 31, 2021
ASSETS
Cash	$	0.3
Goodwill	23.2
Other intangibles, net	83.6
Deferred tax assets	(19.9)
Other assets	2.0
Total assets held-for-sale	$	89.2
LIABILITIES
Total liabilities held-for-sale	$	1.7

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

Intangible Assets (Tables)

12 Months Ended

Oct. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of goodwill

Goodwill


(In millions)	CooperVision		CooperSurgical		Total
Balance at October 31, 2019	$	1,765.4	$	663.5	$	2,428.9
Net additions	13.5		1.8		15.3
Foreign currency translation adjustment	0.4		2.7		3.1
Balance at October 31, 2020	$	1,779.3	$	668.0	$	2,447.3
Net additions	30.2		61.4		91.6
Amount reclassified to assets held for sale (Note 3)	(23.2)		—		(23.2)
Foreign currency translation adjustment	54.7		3.6		58.3
Balance at October 31, 2021	$	1,841.0	$	733.0	$	2,574.0

Schedule of finite-lived intangible assets

Other Intangible Assets


	October 31, 2021				October 31, 2020
(In millions)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization		Weighted Average Amortization Period (in years)
Intangible assets with definite lives:
Trademarks	$	156.7	$	49.1	$	153.4	$	37.7	14
Composite intangible asset	1,061.8		283.2		1,061.9		212.4		15
Technology	513.0		287.9		401.2		251.9		10
Customer relationships	378.4		240.1		367.0		216.2		13
License and distribution rights and other	33.4		21.6		31.8		18.2		10
	2,143.3		$	881.9	2,015.3		$	736.4	14
Less: accumulated amortization and translation	881.9				736.4
Intangible assets with definite lives, net	$	1,261.4			$	1,278.9
Intangible assets with indefinite lives, net (1)	10.1				10.1
Total other intangibles, net	$	1,271.5			$	1,289.0

(1) Intangible assets with indefinite lives include technology and trademarks.

Schedule of indefinite-lived intangible assets

Other Intangible Assets


	October 31, 2021				October 31, 2020
(In millions)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization		Weighted Average Amortization Period (in years)
Intangible assets with definite lives:
Trademarks	$	156.7	$	49.1	$	153.4	$	37.7	14
Composite intangible asset	1,061.8		283.2		1,061.9		212.4		15
Technology	513.0		287.9		401.2		251.9		10
Customer relationships	378.4		240.1		367.0		216.2		13
License and distribution rights and other	33.4		21.6		31.8		18.2		10
	2,143.3		$	881.9	2,015.3		$	736.4	14
Less: accumulated amortization and translation	881.9				736.4
Intangible assets with definite lives, net	$	1,261.4			$	1,278.9
Intangible assets with indefinite lives, net (1)	10.1				10.1
Total other intangibles, net	$	1,271.5			$	1,289.0

(1) Intangible assets with indefinite lives include technology and trademarks.

Remaining amortization expenses for intangible assets with definite lives

As of October 31, 2021, the estimate of future amortization expenses for intangible assets with definite lives is as follows:


Fiscal years:	(In millions)
2022	$	149.2
2023	146.9
2024	142.7
2025	132.2
Thereafter	690.4
Total remaining amortization for intangible assets with definite lives	$	1,261.4

Debt (Tables)

12 Months Ended

Oct. 31, 2021

Debt Disclosure [Abstract]

Schedule of debt


October 31, (In millions)	2021		2020


Overdraft and other credit facilities	$	83.0	$	59.4
Term loans	—		350.0
Less: unamortized debt issuance cost	(0.1)		(0.1)
Short-term debt	$	82.9	$	409.3

Revolving credit	$	546.1	$	534.0
Term loans	850.0		850.0
Other	0.2		0.2
Less: unamortized debt issuance cost	(0.2)		(0.3)
Long-term debt	$	1,396.1	$	1,383.9

Total debt	$	1,479.0	$	1,793.2

The following is a summary of the maximum commitments and the net amounts available to the Company under the credit facilities discussed above as of October 31, 2021:


(In millions)	Facility Limit		Outstanding Borrowings		Outstanding Letters of Credit		Total Amount Available		Maturity Date
2020 Revolving Credit Facility	$	1,290.0	$	546.1	$	1.3	$	742.6	April 1, 2025
2020 Term Loan Facility	850.0		850.0		n/a		—		April 1, 2025
Total	$	2,140.0	$	1,396.1	$	1.3	$	742.6

Maturities of long-term debt

Fiscal year maturities of long-term debt as of October 31, 2021, are as follows:


Year (In millions)
2022	$	—
2023	$	—
2024	$	—
2025	$	1,396.3
2026	$	—
Thereafter	$	—

Income Taxes (Tables)

12 Months Ended

Oct. 31, 2021

Income Tax Disclosure [Abstract]

Income before income taxes

Components of income before income taxes:


Years Ended October 31, (In millions)	2021		2020		2019
Income before income taxes:
United States	$	(31.0)	$	(88.0)	$	(32.8)
Foreign	522.5		354.5		510.2
	$	491.5	$	266.5	$	477.4

Provision for income taxes

Components of provision for income taxes:


Years Ended October 31, (In millions)	2021		2020		2019
Current:
Federal	$	21.0	$	1.4	$	9.2
State	1.3		1.1		1.6
Foreign	26.7		26.5		15.8
	49.0		29.0		26.6

Deferred:
Federal	(8.8)		3.2		(8.1)
State	(0.5)		0.8		(0.9)
Foreign	(2,492.9)		(4.9)		(6.9)
	(2,502.2)		(0.9)		(15.9)
Provision for income taxes	$	(2,453.2)	$	28.1	$	10.7

Reconciliation between the expected provision for income taxes at the US federal statutory rate and the provision for income taxes

Reconciliation between the expected provision for income taxes at the US federal statutory rate and the provision for income taxes:


Years Ended October 31, (In millions)	2021		2020		2019
Provision for income taxes at United States statutory tax rate	$	103.2	$	56.0	$	100.3
(Decrease) increase in taxes resulting from:
Foreign income subject to different tax rates	(43.6)		(54.7)		(85.6)
Foreign income subject to United States tax	25.4		32.0		16.1
United States tax reform	—		—		(5.8)
Employee compensation	(9.9)		(4.4)		(7.8)
Deferred tax asset step-up	3.2		(9.0)		(6.7)
United States provision-to-return	(1.2)		7.0		4.4
Intra-group transfer to UK subsidiary	(1,987.9)		—		—
Remeasurement of deferred tax assets from UK rate change	(536.7)		—		—
Change in unrecognized tax benefits	(7.6)		(0.1)		(1.5)
Other, net	1.9		1.3		(2.7)
Actual provision for income taxes	$	(2,453.2)	$	28.1	$	10.7

Deferred tax assets and liabilities

Components of deferred tax assets and liabilities:


Years Ended October 31, (In millions)	2021		2020
Deferred tax assets:
Accounts receivable, principally due to allowances for doubtful accounts	$	3.4	$	2.6
Inventories	6.1		5.8
Accrued liabilities, reserves and compensation accruals	78.1		77.1
Foreign deferred tax assets	2,531.5		90.9
Share-based compensation	28.6		21.4
Net operating loss carryforwards	18.5		9.6
Intangible assets	7.5		19.6
Research and experimental expenses - Section 59(e)	13.5		9.2
Tax credit carryforwards	0.8		1.5
Total gross deferred tax assets	2,688.0		237.7
Less: valuation allowance	(51.8)		(45.3)
Deferred tax assets	2,636.2		192.4
Deferred tax liabilities:
Tax deductible goodwill	(34.0)		(29.7)
Plant and equipment	(46.5)		(39.2)
Deferred tax on foreign earnings	(8.4)		(7.5)
Transaction costs	(0.7)		(0.7)
Foreign deferred tax liabilities	(24.1)		(61.0)


Total gross deferred tax liabilities	(113.7)		(138.1)
Net deferred tax assets	$	2,522.5	$	54.3

Changes in unrecognized tax benefits

Changes in unrecognized tax benefits:


(In millions)
Balance at October 31, 2019	$	49.7
Increase from prior year's UTB's	3.4
Increase from current year's UTB's	7.6

UTB (decrease) from expiration of statute of limitations	(2.2)

Balance at October 31, 2020	$	58.5
Decrease from prior year's UTB's	(8.3)
Increase from current year's UTB's	307.2
Increase (decrease) from settlements	(1.9)

UTB (decrease) from expiration of statute of limitations	(1.7)

Balance at October 31, 2021	$	353.8

Earnings Per Share (Tables)

12 Months Ended

Oct. 31, 2021

Earnings Per Share [Abstract]

Schedule of earnings per share


Years Ended October 31,
(In millions, except for earnings per share)	2021		2020		2019
Net income attributable to Cooper stockholders	$	2,944.7	$	238.4	$	466.7
Basic:
Weighted average common shares	49.2		49.1		49.4
Basic earnings per share attributable to Cooper stockholders	$	59.80	$	4.85	$	9.44
Diluted:
Weighted average common shares	49.2		49.1		49.4
Effect of dilutive stock plans	0.6		0.5		0.6
Diluted weighted average common shares	49.8		49.6		50.0
Diluted earnings per share attributable to Cooper stockholders	$	59.16	$	4.81	$	9.33

Stock options to purchase common stock and restricted stock units not included in diluted earnings per share calculation due to antidilutive effect


Years Ended October 31,
(In thousands, except exercise prices)	2021		2020		2019
Stock option shares excluded	107		207		198
Exercise prices	$	345.74	$	304.54	$	254.77
Restricted stock units excluded	2		1		8

Stockholders' Equity (Tables)

12 Months Ended

Oct. 31, 2021

Stockholders' Equity Note [Abstract]

Changes in accumulated other comprehensive (loss) income

Analysis of Changes in Accumulated Other Comprehensive Income (Loss):


(In millions)	Foreign Currency Translation Adjustment		Derivatives		Minimum Pension Liability		Total
Balance at October 31, 2018	$	(412.2)	$	—	$	(18.5)	$	(430.7)
Gross change in value	9.0		—		(33.4)		(24.4)
Tax effect	—		—		8.0		8.0

Balance at October 31, 2019	$	(403.2)	$	—	$	(43.9)	$	(447.1)
Gross change in value	$	0.9	$	(17.1)	$	(16.8)	$	(33.0)
Tax effect	—		4.1		4.0		8.1

Balance at October 31, 2020	$	(402.3)	$	(13.0)	$	(56.7)	$	(472.0)
Gross change in value	$	82.2	$	34.3	$	29.8	$	146.3

Tax effect	(0.2)		(8.2)		(7.2)		(15.6)
Balance at October 31, 2021	$	(320.3)	$	13.1	$	(34.1)	$	(341.3)

The following table details the changes in accumulated other comprehensive income:


(In millions)	Amount
Balance as of October 31, 2019	$	—
Amount recognized in other comprehensive income on interest rate swap contracts, gross ($(15.8), net of tax)	(20.8)
Amount reclassified from other comprehensive income into earnings, gross ($2.8, net of tax)	3.7
Balance loss as of October 31, 2020	$	(17.1)
Amount recognized in other comprehensive income on interest rate swap contracts, gross ($20.0, net of tax)	26.3
Amount reclassified from other comprehensive income into earnings, gross ($6.1, net of tax)	8.0
Balance gain as of October 31, 2021	$	17.2

Schedule of share repurchases

For the years ended October 31, 2021 and 2020, the Company share repurchases were as follow:


Years Ended October 31,	2021		2020
Number of shares	69,622		160,850
Average repurchase price per share	$	356.6	$	296.9
Total costs of shares repurchased (in millions)	$	24.8	$	47.8

Stock Plans (Tables)

12 Months Ended

Oct. 31, 2021

Share-based Payment Arrangement [Abstract]

Compensation expense and related income tax benefit for share-based awards

Compensation expense and the related tax benefit recognized in our Consolidated Statements of Income for share-based awards, including the Employee Stock Purchase Plan, were as follows:


October 31,
(In millions)	2021		2020		2019
Selling, general and administrative expense	$	38.4	$	32.2	$	28.7
Cost of sales	3.9		4.0		4.7
Research and development expense	2.4		2.4		2.9
Total compensation expense	$	44.7	$	38.6	$	36.3
Related income tax benefit	$	5.6	$	4.8	$	5.1

Assumptions used in estimating fair value of stock options award granted


Years Ended October 31,	2021		2020		2019
Expected life	4.0 years		4.4 years		4.4 years
Expected volatility	30.3	%	24.5	%	22.0	%
Risk-free interest rate	0.3	%	1.6	%	2.9	%
Dividend yield	0.02	%	0.02	%	0.02	%

Schedule of stock option plans

The activity and status of our stock option plans are summarized below:


	Number of Shares	Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at October 31, 2020	1,103,507	$	213.53
Granted	109,440	$	345.74
Exercised	(235,478)	$	142.31
Forfeited or expired	(4,777)	$	327.62
Outstanding at October 31, 2021	972,692	$	245.09	6.22
Vested and expected to vest at October 31, 2021	939,788	$	243.15	6.16	$	163,310,445
Vested and exercisable at October 31, 2021	470,748	$	207.13	4.99	$	98,757,454

Schedule of non-vested RSUs

The status of our non-vested RSUs is summarized below:


	Number of Shares	Weighted- Average Grant Date Fair Value Per Share
Non-vested RSUs at October 31, 2020	368,620	$	247.09
Granted	114,111	$	352.92
Vested and issued	(137,119)	$	222.42
Forfeited or expired	(28,277)	$	269.62
Non-vested RSUs at October 31, 2021	317,335	$	293.80

Employee Benefits (Tables)

12 Months Ended

Oct. 31, 2021

Retirement Benefits [Abstract]

Changes in benefit obligation, changes in plan assets and funded status

Retirement Income Plan


Years Ended October 31, (In millions)	2021		2020		2019
Change in benefit obligation
Benefit obligation, beginning of year	$	218.8	$	189.7	$	147.1
Service cost	17.2		13.9		10.1
Interest cost	4.4		5.2		6.1
Benefits paid	(11.5)		(10.0)		(10.2)

Actuarial loss	2.0		20.0		36.6
Benefit obligation, end of year	$	230.9	$	218.8	$	189.7
Change in plan assets
Fair value of plan assets, beginning of year	$	159.5	$	136.0	$	121.0
Actual return on plan assets	38.8		10.1		12.1
Employer contributions	12.7		23.4		13.1
Benefits paid	(11.5)		(10.0)		(10.2)
Fair value of plan assets, end of year	$	199.5	$	159.5	$	136.0
Funded status at end of year	$	(31.4)	$	(59.3)	$	(53.7)

Amounts recognized in the consolidated balance sheets


Years Ended October 31, (In millions)	2021		2020		2019
Amounts recognized in the Consolidated Balance Sheets consist of:


Noncurrent liabilities	$	(31.4)	$	(59.3)	$	(53.7)
Net amount recognized at year end	$	(31.4)	$	(59.3)	$	(53.7)

Amounts recognized in accumulated other comprehensive Income


Years Ended October 31, (In millions)	2021		2020		2019
Amounts recognized in accumulated other comprehensive income consist of:


Net loss	$	44.4	$	74.2	$	57.3
Accumulated other comprehensive income	$	44.4	$	74.2	$	57.3

Pension plans with projected benefit obligation in excess of plan assets


Years Ended October 31, (In millions)	2021		2020		2019
Information for defined benefit plans with projected benefit obligation in excess of plan assets:
Projected benefit obligation	$	230.9	$	218.8	$	189.7
Fair value of plan assets	$	199.5	$	159.5	$	136.0

Pension plans with accumulated benefit obligations in excess of fair value of plan assets


Years Ended October 31, (In millions)	2021		2020		2019
Information for defined benefit plans with accumulated benefit obligations in excess of plan assets:
Accumulated benefit obligation	$	207.6	$	195.8	$	170.8
Fair value of plan assets	$	199.5	$	159.5	$	136.0

Reconciliation of prepaid (accrued) pension cost


Years Ended October 31, (In millions)	2021		2020		2019
Reconciliation of (prepaid) accrued pension cost:
(Prepaid)/Accrued pension cost at prior fiscal year end	$	(14.8)	$	(3.7)	$	2.2
Net periodic benefit cost	14.5		12.3		7.2
Contributions made during the year	(12.7)		(23.4)		(13.1)

(Prepaid)/Accrued pension cost at fiscal year end	$	(13.0)	$	(14.8)	$	(3.7)

Components of net periodic pension costs and other amounts recognized in other comprehensive income


Years Ended October 31, (In millions)	2021		2020		2019
Components of net periodic benefit cost and other amounts recognized in the Consolidated Statements of Income:
Net periodic benefit cost:
Service cost	$	17.2	$	13.9	$	10.1
Interest cost	4.4		5.2		6.1
Expected return on plan assets	(12.5)		(10.8)		(9.8)


Recognized actuarial loss	5.4		4.0		0.8
Net periodic pension cost	$	14.5	$	12.3	$	7.2

Other changes in plan assets and benefit obligations recognized in other comprehensive income


Years Ended October 31, (In millions)	2021		2020		2019
Other changes in plan assets and benefit obligations recognized in other comprehensive income:


Net (gain) loss	$	(24.4)	$	20.8	$	34.2


Amortizations of net gain	(5.4)		(4.0)		(0.8)



Total recognized in other comprehensive (income) loss	$	(29.8)	$	16.8	$	33.4
Total recognized in net periodic benefit cost and other comprehensive (income) loss	$	(15.2)	$	29.0	$	40.6

Weighted-average assumptions used in computing net periodic pension cost and projected benefit obligation


Years Ended October 31,	2021		2020		2019
Weighted-average assumptions used in computing the net periodic pension cost and projected benefit obligation at year end:
Discount rate for determining net periodic pension cost:
Projected Benefit Obligation	2.78	%	3.13	%	4.42	%
Service Cost	2.86	%	3.18	%	4.49	%
Interest Cost	2.07	%	2.78	%	4.22	%
Discount rate for determining benefit obligations at year end	2.76	%	2.78	%	3.13	%
Rate of compensation increase for determining expense	3.60	%	3.60	%	4.00	%
Rate of compensation increase for determining benefit obligations at year end	3.60	%	3.60	%	3.60	%
Expected rate of return on plan assets for determining net periodic pension cost	8.00	%	8.00	%	8.00	%
Expected rate of return on plan assets at year end	8.00	%	8.00	%	8.00	%
Measurement date for determining assets and benefit obligations at year end	10/31/2021		10/31/2020		10/31/2019

Weighted-average asset allocations and fair value measurement of plan assets

Plan Assets

Weighted-average asset allocations at year end, by asset category are as follows:


Years Ended October 31,	2021		2020		2019
Asset category
Cash and cash equivalents	5.0	%	11.8	%	3.2	%

Equity mutual funds	62.8	%	57.7	%	63.7	%
Hedging Strategy Funds	4.7	%	4.3	%	4.9	%

Bond mutual funds	27.5	%	26.2	%	28.2	%
Total	100.0	%	100.0	%	100.0	%

As of the measurement date of October 31, 2021, the fair value measurement of plan assets is as follows:


(In millions)	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Asset category
Cash and cash equivalents	$	10.0	$	10.0	$	—	$	—

Equity mutual funds	125.3		125.3		—		—
Hedging Strategy Funds	9.4		9.4		—		—
Bond mutual funds	54.8		24.5		30.2		0.1
Total	$	199.5	$	169.2	$	30.2	$	0.1

Estimated future benefit payments

Estimated Future Benefit Payments


Years (In millions)
2022	$	10.7
2023	$	11.6
2024	$	12.8
2025	$	13.7
2026	$	14.4
2027-2031	$	79.6

Business Segment Information (Tables)

12 Months Ended

Oct. 31, 2021

Segment Reporting [Abstract]

Schedule of business segment net sales

The following table presents a summary of our business segment net sales:


(In millions)	2021		2020		2019
CooperVision net sales by category:
Toric lens	$	697.5	$	598.2	$	620.0
Multifocal lens	238.6		197.0		202.9
Single-use sphere lens	616.3		529.0		568.2
Non single-use sphere, other	599.6		518.8		581.8
Total CooperVision net sales	2,152.0		1,843.0		1,972.9
CooperSurgical net sales by category:
Office and surgical products	451.3		358.8		422.4
Fertility	319.2		229.1		258.1
Total CooperSurgical net sales	770.5		587.9		680.5
Total net sales	$	2,922.5	$	2,430.9	$	2,653.4

Schedule of business segment information

Information by business segment for each of the years in the three-year period ended October 31, 2021, follows:


(In millions)	CooperVision		CooperSurgical		Corporate		Consolidated
2021
Net sales	$	2,152.0	$	770.5	$	—	$	2,922.5
Operating income (loss)	$	481.3	$	71.8	$	(47.3)	$	505.8
Interest expense							23.1
Other (income), net							(8.8)
Income before income taxes							$	491.5
Identifiable assets	$	6,965.9	$	2,395.6	$	244.7	$	9,606.2
Depreciation expense	$	148.3	$	14.9	$	—	$	163.2
Amortization expense	$	35.7	$	110.4	$	—	$	146.1
Capital expenditures	$	190.0	$	24.4	$	—	$	214.4
2020
Net sales	$	1,843.0	$	587.9	$	—	$	2,430.9
Operating income (loss)	$	375.7	$	(14.7)	$	(49.2)	$	311.8
Interest expense							36.8
Other expense, net							8.5
Income before income taxes							$	266.5
Identifiable assets	$	4,236.3	$	2,293.8	$	207.4	$	6,737.5
Depreciation expense	$	138.2	$	11.7	$	—	$	149.9
Amortization expense	$	32.4	$	104.8	$	—	$	137.2
Capital expenditures	$	260.3	$	50.1	$	—	$	310.4
2019
Net sales	$	1,972.9	$	680.5	$	—	$	2,653.4
Operating income (loss)	$	506.4	$	87.9	$	(47.6)	$	546.7
Interest expense							68.0
Other expense, net							1.3
Income before income taxes							$	477.4
Identifiable assets	$	3,911.6	$	2,189.8	$	173.1	$	6,274.5
Depreciation expense	$	125.8	$	9.0	$	0.2	$	135.0
Amortization expense	$	40.9	$	104.9	$	—	$	145.8
Capital expenditures	$	259.0	$	33.1	$	—	$	292.1

Schedule of information by geographical area by country of domicile

Information by geographical area by country of domicile for each of the years in the three-year period ended October 31, 2021, follows:


(In millions)	United States		Europe		Rest of World, Other Eliminations & Corporate		Consolidated
2021
Net sales to unaffiliated customers	$	1,339.2	$	957.9	$	625.4	$	2,922.5
Sales between geographic areas	494.9		815.1		(1,310.0)		—
Net sales	$	1,834.1	$	1,773.0	$	(684.6)	$	2,922.5
Operating (loss) income	$	(26.8)	$	416.2	$	116.4	$	505.8
Long-lived assets	$	737.5	$	377.2	$	232.9	$	1,347.6
2020
Net sales to unaffiliated customers	$	1,103.6	$	789.8	$	537.5	$	2,430.9
Sales between geographic areas	391.7		327.1		(718.8)		—
Net sales	$	1,495.3	$	1,116.9	$	(181.3)	$	2,430.9
Operating (loss) income	$	(14.5)	$	21.9	$	304.4	$	311.8
Long-lived assets	$	721.3	$	363.0	$	197.6	$	1,281.9
2019
Net sales to unaffiliated customers	$	1,211.8	$	854.8	$	586.8	$	2,653.4
Sales between geographic areas	650.7		300.8		(951.5)		—
Net sales	$	1,862.5	$	1,155.6	$	(364.7)	$	2,653.4
Operating income	$	83.2	$	29.3	$	434.2	$	546.7
Long-lived assets	$	626.5	$	358.8	$	146.8	$	1,132.1

Financial Derivatives and Hedging (Tables)

12 Months Ended

Oct. 31, 2021

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Outstanding derivatives designated as hedging instruments

As of October 31, 2021, the Company had the following outstanding derivatives designated as hedging instruments:


(In millions, except for number of instruments)	Number of Instruments	Notional Value
Interest Rate Swap Contracts	3	$	1,000

Fair values of derivative instruments in condensed consolidated balance sheets


	Derivative Assets
(In millions)			October 31, 2021		October 31, 2020
Derivatives designated as cash flow hedges		Balance sheet location
Interest rate swap contracts		Other current assets	$	—	$	—
Interest rate swap contracts		Other non-current assets	17.2		—
			$	17.2	$	—


	Derivative Liabilities
(In millions)			October 31, 2021		October 31, 2020
Derivatives designated as cash flow hedges		Balance sheet location
Interest rate swap contracts		Other current liabilities	$	—	$	0.6
Interest rate swap contracts		Other non-current liabilities	—		16.5
			$	—	$	17.1

Derivative instruments recognized in condensed consolidated statements of income

The following table summarizes the amounts recognized with respect to our derivative instruments within the accompanying Consolidated Statements of Income:


Periods Ended October 31,
(In millions)		2021		2020		2019
Derivatives designated as cash flow hedges	Location of Loss Recognized on Derivatives
Interest rate swap contracts	Interest expense	$	8.0	$	3.7	$	—

Changes in accumulated other comprehensive (loss) income

Analysis of Changes in Accumulated Other Comprehensive Income (Loss):


(In millions)	Foreign Currency Translation Adjustment		Derivatives		Minimum Pension Liability		Total
Balance at October 31, 2018	$	(412.2)	$	—	$	(18.5)	$	(430.7)
Gross change in value	9.0		—		(33.4)		(24.4)
Tax effect	—		—		8.0		8.0

Balance at October 31, 2019	$	(403.2)	$	—	$	(43.9)	$	(447.1)
Gross change in value	$	0.9	$	(17.1)	$	(16.8)	$	(33.0)
Tax effect	—		4.1		4.0		8.1

Balance at October 31, 2020	$	(402.3)	$	(13.0)	$	(56.7)	$	(472.0)
Gross change in value	$	82.2	$	34.3	$	29.8	$	146.3

Tax effect	(0.2)		(8.2)		(7.2)		(15.6)
Balance at October 31, 2021	$	(320.3)	$	13.1	$	(34.1)	$	(341.3)

The following table details the changes in accumulated other comprehensive income:


(In millions)	Amount
Balance as of October 31, 2019	$	—
Amount recognized in other comprehensive income on interest rate swap contracts, gross ($(15.8), net of tax)	(20.8)
Amount reclassified from other comprehensive income into earnings, gross ($2.8, net of tax)	3.7
Balance loss as of October 31, 2020	$	(17.1)
Amount recognized in other comprehensive income on interest rate swap contracts, gross ($20.0, net of tax)	26.3
Amount reclassified from other comprehensive income into earnings, gross ($6.1, net of tax)	8.0
Balance gain as of October 31, 2021	$	17.2

Accounting Policies - Narrative (Details)	3 Months Ended	12 Months Ended
Accounting Policies - Narrative (Details)	Jul. 31, 2021 USD ($)	Oct. 31, 2021 USD ($) business_unit shares	Oct. 31, 2020 USD ($) shares	Oct. 31, 2019 USD ($)	Oct. 31, 2018 USD ($)
Property, Plant and Equipment [Line Items]
Number of business units \| business_unit		2
Refund liability for product returns		$ 13,700,000	$ 10,000,000
Goodwill impairment	$ 0	0	0
Cumulative-effect adjustment upon adoption of accounting standards update		(6,942,000,000)	(3,824,800,000)	$ (3,628,600,000)	$ (3,307,800,000)
Net foreign exchange loss		5,500,000	1,200,000	2,200,000
Interest capitalized included in construction in progress		$ 7,800,000	$ 5,300,000
Treasury stock (in shares) \| shares		4,400,000	4,300,000
Treasury stock repurchase (in shares) \| shares		69,622	160,850
Retained Earnings
Property, Plant and Equipment [Line Items]
Cumulative-effect adjustment upon adoption of accounting standards update		$ (6,202,100,000)	$ (3,261,800,000)	$ (3,026,400,000)	(2,576,000,000)
Cumulative Effect, Period of Adoption, Adjustment
Property, Plant and Equipment [Line Items]
Cumulative-effect adjustment upon adoption of accounting standards update			1,400,000		13,300,000
Cumulative Effect, Period of Adoption, Adjustment \| Retained Earnings
Property, Plant and Equipment [Line Items]
Cumulative-effect adjustment upon adoption of accounting standards update			$ 1,400,000		$ 13,300,000
Minimum
Property, Plant and Equipment [Line Items]
Capitalized contract cost, amortization period (or less)		1 year
Minimum \| Building
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life		30 years
Minimum \| Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life		3 years
Maximum \| Building
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life		40 years
Maximum \| Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life		15 years

Accounting Policies - Inventory (Details) - USD ($) $ in Millions	Oct. 31, 2021	Oct. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 137.7	$ 151.0
Work-in-process	14.0	12.4
Finished goods	433.9	407.0
Inventories, net	$ 585.6	$ 570.4

Accounting Policies - Property Plant and Equipment (Details) - USD ($) $ in Millions	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	$ 2,655.7	$ 2,474.8
Less: Accumulated depreciation	1,308.1	1,192.9
Property, plant and equipment, net	1,347.6	1,281.9	$ 1,132.1
Land and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	20.3	19.9
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	388.0	356.1
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	1,863.6	1,764.9
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	$ 383.8	$ 333.9

Leases - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
Leases - Narrative (Details) - USD ($) $ in Millions	Oct. 31, 2019	Oct. 31, 2021	Oct. 31, 2020
Leases [Abstract]
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]		Other current liabilities	Other current liabilities
Commitments under finance lease arrangements		$ 2.0	$ 2.4
Operating leases, rent expense	$ 45.3

Leases - Leases on the Consolidated Condensed Balance Sheet (Details) - USD ($) $ in Millions	Oct. 31, 2021	Oct. 31, 2020
Operating Leases
Operating lease right-of-use assets	$ 257.0	$ 260.2
Operating lease liabilities, current	35.7	33.3
Operating lease liabilities, non-current	231.7	236.8
Total operating lease liabilities	$ 267.4	$ 270.1
Weighted average remaining lease term (in years)	10 years 7 months 6 days	11 years 3 months 18 days
Weighted average discount rate	3.00%	3.00%

Leases - Lease Expense on Consolidated Statements of Income (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Leases [Abstract]
Operating lease expense	$ 44.1	$ 41.2
Short-term lease expense	0.9	4.4
Variable lease expense	$ 0.4	$ 1.8

Leases - Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 37.4	$ 40.6
Operating lease right-of-use assets obtained in exchange for lease obligations	$ 26.5	$ 17.7

Leases - Minimum Rental Payments Required Under Operating Leases (Details) - USD ($) $ in Millions	Oct. 31, 2021	Oct. 31, 2020
Leases [Abstract]
2022	$ 42.5
2023	37.3
2024	31.9
2025	30.2
2026	29.4
Thereafter	146.3
Total lease payments	317.6
Less: interest	50.2
Present value of lease liabilities	$ 267.4	$ 270.1

Acquisitions and Assets Held for Sale - Total Purchase Consideration for Business and Asset Acquisitions (Details) - USD ($) $ in Millions	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Goodwill	$ 2,574.0	$ 2,447.3	$ 2,428.9
Series Of Individually Immaterial Business Acquisitions And Asset Acquisitions
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Total identifiable intangible assets	208.0	20.4	30.1
Goodwill	91.6	15.3	29.8
Net tangible (liabilities) assets	(10.8)	(0.3)	7.3
Fair value of contingent consideration	(39.1)	0.0	0.0
Total closing purchase price	249.7	35.4	67.2
Series Of Individually Immaterial Business Acquisitions And Asset Acquisitions \| Technology
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Total identifiable intangible assets	178.6	0.0	12.3
Series Of Individually Immaterial Business Acquisitions And Asset Acquisitions \| In-Process Research & Development (IPR&D)
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Total identifiable intangible assets	20.0	0.0	0.0
Series Of Individually Immaterial Business Acquisitions And Asset Acquisitions \| Customer relationships
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Total identifiable intangible assets	7.5	11.4	7.5
Series Of Individually Immaterial Business Acquisitions And Asset Acquisitions \| Trademarks
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Total identifiable intangible assets	1.3	5.1	10.2
Series Of Individually Immaterial Business Acquisitions And Asset Acquisitions \| Other
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Total identifiable intangible assets	$ 0.6	$ 3.9	$ 0.1

Acquisitions and Assets Held for Sale - Narrative (Details) - USD ($)			3 Months Ended	12 Months Ended
	Feb. 02, 2021	Jan. 19, 2021	Jan. 31, 2022	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019	Feb. 01, 2021
Business Acquisition [Line Items]
Goodwill				$ 2,574,000,000	$ 2,447,300,000	$ 2,428,900,000
Contingent consideration, change in fair value				66,100,000	$ 0	$ 0
Equity Interest In Wholly-Owned Subsidiary \| Disposal Group, Held-for-sale, Not Discontinued Operations
Business Acquisition [Line Items]
Percentage of voting interests sold	50.00%
Ownership interest retained after sale of business	50.00%
Asset impairment				0
Privately-Held Medical Device Company, Developed Mara Water Vapor Ablation System
Business Acquisition [Line Items]
Goodwill							$ 0
Privately-Held Medical Device Company, Spectacle Lenses
Business Acquisition [Line Items]
Equity investment gain realized before acquisition of remaining equity interest		$ 11,500,000
Payments to acquire business		40,900,000
Contingent consideration		37,900,000
Contingent consideration paid				0
Contingent consideration, change in fair value				$ 56,800,000
Privately-Held Medical Device Company, Spectacle Lenses, Portion Attributable To Former Equity Interest Owners
Business Acquisition [Line Items]
Undiscounted range of the contingent consideration, minimum		0
Undiscounted range of the contingent consideration, maximum		139,100,000
Contingent consideration		$ 30,200,000
Generate Life Sciences \| Subsequent Event \| Forecast
Business Acquisition [Line Items]
Payments to acquire business			$ 1,605,000,000

Acquisitions and Assets Held for Sale - Contingent Consideration Reconciliation (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 0.0	$ 0.0
Purchase price contingent consideration	31.3	0.0
Payments	0.0	0.0
Change in fair value	66.1	0.0
Ending balance	$ 97.4	$ 0.0

Acquisitions and Assets Held for Sale - Carrying Amounts of the Assets and Liabilities Held for Sale (Details) - USD ($) $ in Millions	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
ASSETS
Cash	$ 0.3	$ 0.0	$ 0.0
Disposal Group, Held-for-sale, Not Discontinued Operations \| Equity Interest In Wholly-Owned Subsidiary
ASSETS
Cash	0.3
Goodwill	23.2
Other intangibles, net	83.6
Deferred tax assets	(19.9)
Other assets	2.0
Total assets held-for-sale	89.2
LIABILITIES
Total liabilities held-for-sale	$ 1.7

Intangible Assets - Goodwill (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Goodwill [Roll Forward]
Balance, beginning	$ 2,447.3	$ 2,428.9
Net additions	91.6	15.3
Foreign currency translation adjustment	58.3	3.1
Amount reclassified to assets held for sale	(23.2)
Balance, ending	2,574.0	2,447.3
CooperVision
Goodwill [Roll Forward]
Balance, beginning	1,779.3	1,765.4
Net additions	30.2	13.5
Foreign currency translation adjustment	54.7	0.4
Amount reclassified to assets held for sale	(23.2)
Balance, ending	1,841.0	1,779.3
CooperSurgical
Goodwill [Roll Forward]
Balance, beginning	668.0	663.5
Net additions	61.4	1.8
Foreign currency translation adjustment	3.6	2.7
Amount reclassified to assets held for sale	0.0
Balance, ending	$ 733.0	$ 668.0

Intangible Assets - Narrative (Details)	3 Months Ended	12 Months Ended
Intangible Assets - Narrative (Details)	Jul. 31, 2021 USD ($)	Oct. 31, 2021 USD ($) reporting_unit	Oct. 31, 2020 USD ($)
Goodwill [Line Items]
Goodwill impairment	$ 0	$ 0	$ 0
Number of reporting units \| reporting_unit		3
Impairment of definite-lived intangible assets		$ 0
Impairment of indefinite-lived intangible assets		0
CooperSurgical
Goodwill [Line Items]
Goodwill deductible for tax purposes		137,200,000	134,200,000
CooperVision
Goodwill [Line Items]
Goodwill deductible for tax purposes		$ 24,600,000	$ 26,900,000

Intangible Assets - Other Intangible Assets (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 2,143.3	$ 2,015.3
Accumulated Amortization	881.9	736.4
Intangible assets with definite lives, net	$ 1,261.4	1,278.9
Weighted Average Amortization Period (in years)	14 years
Intangible assets with indefinite lives, net	$ 10.1	10.1
Total other intangibles, net	1,271.5	1,289.0
Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	156.7	153.4
Accumulated Amortization	$ 49.1	37.7
Weighted Average Amortization Period (in years)	14 years
Composite intangible asset
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,061.8	1,061.9
Accumulated Amortization	$ 283.2	212.4
Weighted Average Amortization Period (in years)	15 years
Technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 513.0	401.2
Accumulated Amortization	$ 287.9	251.9
Weighted Average Amortization Period (in years)	10 years
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 378.4	367.0
Accumulated Amortization	$ 240.1	216.2
Weighted Average Amortization Period (in years)	13 years
License and distribution rights and other
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 33.4	31.8
Accumulated Amortization	$ 21.6	$ 18.2
Weighted Average Amortization Period (in years)	10 years

Intangible Assets - Estimated Amortization Expenses for Intangible Assets with Definite Lives (Details) - USD ($) $ in Millions	Oct. 31, 2021	Oct. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
2022	$ 149.2
2023	146.9
2024	142.7
2025	132.2
Thereafter	690.4
Intangible assets with definite lives, net	$ 1,261.4	$ 1,278.9

Debt - Total Debt (Details) - USD ($) $ in Millions	Oct. 31, 2021	Oct. 31, 2020
Short-term Debt
Less: unamortized debt issuance cost	$ (0.1)	$ (0.1)
Short-term debt	82.9	409.3
Long-term Debt
Less: unamortized debt issuance cost	(0.2)	(0.3)
Long-term debt	1,396.1	1,383.9
Total debt	1,479.0	1,793.2
Overdraft and other credit facilities
Short-term Debt
Outstanding Borrowings	83.0	59.4
Term loans
Short-term Debt
Outstanding Borrowings	0.0	350.0
Term loans
Long-term Debt
Long-term debt, gross	850.0	850.0
Other
Long-term Debt
Long-term debt, gross	0.2	0.2
Revolving Credit Facility \| Line of Credit
Long-term Debt
Long-term debt, gross	$ 546.1	$ 534.0

Debt - Maturities of Long-term Debt (Details) $ in Millions	Oct. 31, 2021 USD ($)
Maturities of Long-term Debt [Abstract]
2022	$ 0.0
2023	0.0
2024	0.0
2025	1,396.3
2026	0.0
Thereafter	$ 0.0

Debt - Narrative (Details) - USD ($)				12 Months Ended
Debt - Narrative (Details) - USD ($)	Nov. 02, 2021	Oct. 16, 2020	Apr. 01, 2020	Oct. 31, 2021	Oct. 31, 2020
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Letters of credit outstanding				$ 4,900,000	$ 4,500,000
Term Loan Agreement 2021 \| Term loans \| Subsequent Event
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Debt term	364 days
Original debt amount	$ 840,000,000
Term Loan Agreement 2021 \| Term loans \| London Interbank Offered Rate (LIBOR) \| Subsequent Event
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate	0.60%
Term Loan Agreement 2020 \| Term loans
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Debt term		364 days
Original debt amount		$ 350,000,000
Credit Agreement 2020 \| Line of Credit
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Aggregate principal amount				2,140,000,000
Debt outstanding				1,396,100,000
Credit Agreement 2020 \| Line of Credit \| Revolving Credit Facility
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Aggregate principal amount			$ 1,290,000,000	1,290,000,000
Proceeds from line of credit			$ 445,000,000
Debt outstanding				$ 546,100,000
Interest rate				0.96%
Letters of credit outstanding				$ 1,300,000
Credit Agreement 2020 \| Line of Credit \| Revolving Credit Facility \| Minimum
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Commitment fee percentage			0.10%
Credit Agreement 2020 \| Line of Credit \| Revolving Credit Facility \| Maximum
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Commitment fee percentage			0.20%
Credit Agreement 2020 \| Line of Credit \| Term Loan Facility 2020
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Aggregate principal amount			$ 850,000,000	850,000,000.0
Proceeds from line of credit			850,000,000
Debt outstanding				$ 850,000,000
Interest rate				0.96%
Expensed debt issuance costs				$ 100,000
Credit Agreement 2020 \| Line of Credit \| Revolving Credit Facility And Term Loan Facility 2020
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Potential additional borrowing capacity			$ 1,605,000,000
Required minimum interest coverage ratio			3.00
Required maximum total leverage ratio			3.75
Interest coverage ratio				43.29
Total leverage ratio				1.38
Interest coverage ratio and total leverage ratio, expected minimum compliance period				12 months
Credit Agreement 2020 \| Line of Credit \| Revolving Credit Facility And Term Loan Facility 2020 \| Base Rate \| Minimum
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate			0.00%
Credit Agreement 2020 \| Line of Credit \| Revolving Credit Facility And Term Loan Facility 2020 \| Base Rate \| Maximum
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate			0.50%
Credit Agreement 2020 \| Line of Credit \| Revolving Credit Facility And Term Loan Facility 2020 \| London Interbank Offered Rate (LIBOR) \| Minimum
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate			0.75%
Credit Agreement 2020 \| Line of Credit \| Revolving Credit Facility And Term Loan Facility 2020 \| London Interbank Offered Rate (LIBOR) \| Maximum
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate			1.50%
European Credit Facilities \| Line of Credit \| Revolving Credit Facility
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Aggregate principal amount				$ 35,800,000	25,800,000
Debt outstanding				$ 5,400,000
Weighted average interest rate				0.57%
Asian Pacific Credit Facilities - Yen-Denominated \| Line of Credit \| Revolving Credit Facility
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Aggregate principal amount				$ 95,000,000	76,600,000
Debt outstanding				$ 77,700,000
Weighted average interest rate				0.42%
Asian Pacific Credit Facilities - Asia Pacific Subsidiaries \| Line of Credit \| Revolving Credit Facility
Schedule of Long Term and Short Term Debt Instruments [Line Items]
Aggregate principal amount				$ 9,900,000	$ 11,200,000
Debt outstanding				$ 400,000
Weighted average interest rate				2.54%

Debt - Maximum Commitments and Net Amounts Available under Credit Facilities (Details) - USD ($)	Oct. 31, 2021	Oct. 31, 2020	Apr. 01, 2020
Line of Credit Facility [Line Items]
Outstanding Letters of Credit	$ 4,900,000	$ 4,500,000
Line of Credit \| Credit Agreement 2020
Line of Credit Facility [Line Items]
Facility Limit	2,140,000,000
Outstanding Borrowings	1,396,100,000
Line of Credit \| Credit Agreement 2020 \| Revolving Credit Facility
Line of Credit Facility [Line Items]
Facility Limit	1,290,000,000		$ 1,290,000,000
Outstanding Borrowings	546,100,000
Outstanding Letters of Credit	1,300,000
Total Amount Available	742,600,000
Line of Credit \| Credit Agreement 2020 \| Term Loan Facility 2020
Line of Credit Facility [Line Items]
Facility Limit	850,000,000.0		$ 850,000,000
Outstanding Borrowings	$ 850,000,000

- Definition

The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References + Details

Income Taxes - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
Income Taxes - Narrative (Details) - USD ($) $ in Millions	Oct. 31, 2021	Oct. 31, 2020	Jan. 31, 2021	Oct. 31, 2019
Operating Loss Carryforwards [Line Items]
Effective tax rate	(499.10%)	10.60%
Deferred tax asset, intra-entity sale of certain intellectual property rights			$ 1,987.9
Unrecognized tax benefits	$ 353.8	$ 58.5		$ 49.7
Unrecognized tax benefits that would impact the effective tax rate	336.5	46.0		41.7
Accrued gross interest and penalties related to uncertain tax positions	6.4	$ 7.3		$ 3.9
Significant change in unrecognized tax benefits that is reasonably possible during the next twelve months	4.2
Domestic Tax Authority
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	63.7
Federal net operating losses expiring	47.5
Federal net operating losses not subject to expiration	16.2
State and Local Jurisdiction
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	19.7
Research Tax Credit Carryforward
Operating Loss Carryforwards [Line Items]
Research credit	$ 1.0

Income Taxes - Income Before Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Income before income taxes:
United States	$ (31.0)	$ (88.0)	$ (32.8)
Foreign	522.5	354.5	510.2
Income before income taxes	$ 491.5	$ 266.5	$ 477.4

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

Income Taxes - Income Tax Provision (Benefit) (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Current:
Federal	$ 21.0	$ 1.4	$ 9.2
State	1.3	1.1	1.6
Foreign	26.7	26.5	15.8
Total current income tax expense (benefit)	49.0	29.0	26.6
Deferred:
Federal	(8.8)	3.2	(8.1)
State	(0.5)	0.8	(0.9)
Foreign	(2,492.9)	(4.9)	(6.9)
Total deferred income tax expense (benefit)	(2,502.2)	(0.9)	(15.9)
Provision for income taxes	$ (2,453.2)	$ 28.1	$ 10.7

Income Taxes - Reconciliation between the Expected Provision for Income taxes at the US Federal Statutory Rate and the Provision for Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Income Tax Disclosure [Abstract]
Provision for income taxes at United States statutory tax rate	$ 103.2	$ 56.0	$ 100.3
Foreign income subject to different tax rates	(43.6)	(54.7)	(85.6)
Foreign income subject to United States tax	25.4	32.0	16.1
United States tax reform	0.0	0.0	(5.8)
Employee compensation	(9.9)	(4.4)	(7.8)
Deferred tax asset step-up	3.2	(9.0)	(6.7)
United States provision-to-return	(1.2)	7.0	4.4
Intra-group transfer to UK subsidiary	(1,987.9)	0.0	0.0
Remeasurement of deferred tax assets from UK rate change	(536.7)	0.0	0.0
Change in unrecognized tax benefits	(7.6)	(0.1)	(1.5)
Other, net	1.9	1.3	(2.7)
Provision for income taxes	$ (2,453.2)	$ 28.1	$ 10.7

Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions	Oct. 31, 2021	Oct. 31, 2020
Deferred tax assets:
Accounts receivable, principally due to allowances for doubtful accounts	$ 3.4	$ 2.6
Inventories	6.1	5.8
Accrued liabilities, reserves and compensation accruals	78.1	77.1
Foreign deferred tax assets	2,531.5	90.9
Share-based compensation	28.6	21.4
Net operating loss carryforwards	18.5	9.6
Intangible assets	7.5	19.6
Research and experimental expenses - Section 59(e)	13.5	9.2
Tax credit carryforwards	0.8	1.5
Total gross deferred tax assets	2,688.0	237.7
Less: valuation allowance	(51.8)	(45.3)
Deferred tax assets	2,636.2	192.4
Deferred tax liabilities:
Tax deductible goodwill	(34.0)	(29.7)
Plant and equipment	(46.5)	(39.2)
Deferred tax on foreign earnings	(8.4)	(7.5)
Transaction costs	(0.7)	(0.7)
Foreign deferred tax liabilities	(24.1)	(61.0)
Total gross deferred tax liabilities	(113.7)	(138.1)
Net deferred tax assets	$ 2,522.5	$ 54.3

Income Taxes - Changes in Unrecognized Tax Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning of the period	$ 58.5	$ 49.7
Increase from prior year's UTB's		3.4
Increase from current year's UTB's	307.2	7.6
Decrease from prior year's UTB's	(8.3)
Increase (decrease) from settlements	(1.9)
UTB (decrease) from expiration of statute of limitations	(1.7)	(2.2)
End of the period	$ 353.8	$ 58.5

Earnings Per Share - Basic and Diluted (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Earnings Per Share [Abstract]
Net income, basic	$ 2,944.7	$ 238.4	$ 466.7
Net income, diluted	$ 2,944.7	$ 238.4	$ 466.7
Basic:
Weighted average common shares (in shares)	49.2	49.1	49.4
Basic earnings per share attributable to Cooper stockholders (in dollars per share)	$ 59.80	$ 4.85	$ 9.44
Diluted:
Effect of dilutive stock options (in shares)	0.6	0.5	0.6
Diluted weighted average common shares (in shares)	49.8	49.6	50.0
Diluted earnings per share attributable to Cooper stockholders (in dollars per share)	$ 59.16	$ 4.81	$ 9.33

Earnings Per Share - Stock Options to Purchase Common Stock and Restricted Stock Units Not Included in Diluted Earnings Per Share Due to Antidilutive Effect (Details) - $ / shares shares in Thousands	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Range of exercise prices, lower limit (in dollars per share)	$ 345.74	$ 304.54	$ 254.77
Range of exercise prices, higher limit (in dollars per share)	$ 345.74	$ 304.54	$ 254.77
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Stock option shares and restricted stock units excluded (in shares)	107	207	198
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Stock option shares and restricted stock units excluded (in shares)	2	1	8

Stockholders' Equity - Changes in Accumulated Other Comprehensive Income (Loss) Income (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 3,824.8	$ 3,628.6	$ 3,307.8
Gross change in value	146.3	(33.0)	(24.4)
Tax effect	(15.6)	8.1	8.0
Ending balance	6,942.0	3,824.8	3,628.6
Total
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(472.0)	(447.1)	(430.7)
Ending balance	(341.3)	(472.0)	(447.1)
Foreign Currency Translation Adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(402.3)	(403.2)	(412.2)
Gross change in value	82.2	0.9	9.0
Tax effect	(0.2)	0.0	0.0
Ending balance	(320.3)	(402.3)	(403.2)
Derivatives
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(13.0)	0.0	0.0
Gross change in value	34.3	(17.1)	0.0
Tax effect	(8.2)	4.1	0.0
Ending balance	13.1	(13.0)	0.0
Minimum Pension Liability
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(56.7)	(43.9)	(18.5)
Gross change in value	29.8	(16.8)	(33.4)
Tax effect	(7.2)	4.0	8.0
Ending balance	$ (34.1)	$ (56.7)	$ (43.9)

- Definition

Amount before tax, after reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109237563&loc=d3e33775-111570

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

+ Details

- Definition

Amount of tax expense (benefit) allocated to other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

+ Details

- Definition

Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 23
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(3)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (a)(3)(iii)(03)

+ Details

Stockholders' Equity - Narrative (Details) - USD ($)					12 Months Ended
Stockholders' Equity - Narrative (Details) - USD ($)	Aug. 11, 2021	Feb. 09, 2021	Aug. 07, 2020	Feb. 10, 2020	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019	Mar. 31, 2017	Dec. 31, 2011
Stockholders' Equity Note [Abstract]
Share repurchase program, maximum amount authorized								$ 1,000,000,000	$ 500,000,000
Share repurchase program, remaining authorized amount					$ 334,800,000
Dividends on common stock (in dollars per share)	$ 0.03	$ 0.03	$ 0.03	$ 0.03	$ 0.03	$ 0.03	$ 0.03
Dividends on common stock	$ 1,500,000	$ 1,500,000	$ 1,500,000	$ 1,500,000	$ 3,000,000.0	$ 3,000,000.0	$ 3,000,000.0

Stockholders' Equity - Share Repurchases (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Stockholders' Equity Note [Abstract]
Number of shares	69,622	160,850
Average repurchase price per share (in dollars per share)	$ 356.6	$ 296.9
Total costs of shares repurchased (in millions)	$ 24.8	$ 47.8	$ 156.1

Stock Plans - Narrative (Details)		1 Months Ended		12 Months Ended
Stock Plans - Narrative (Details)	Mar. 18, 2019 USD ($) shares	Mar. 31, 2020 USD ($) director shares	Mar. 31, 2016 director shares	Oct. 31, 2021 USD ($) $ / shares shares	Oct. 31, 2020 USD ($) $ / shares shares	Oct. 31, 2019 USD ($) $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost related to nonvested options				$ 21,000,000
Share-based compensation expense				$ 44,700,000	$ 38,600,000	$ 36,300,000
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted in period (in shares) \| shares				109,440
Total unrecognized compensation cost expected to be recognized over a remaining weighted-average vesting period				2 years 8 months 12 days
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost expected to be recognized over a remaining weighted-average vesting period				2 years 9 months 18 days
Total unrecognized compensation cost related to nonvested units				$ 63,100,000
Performance Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period				3 years
Total unrecognized compensation cost expected to be recognized over a remaining weighted-average vesting period				2 years 3 months 18 days
Total unrecognized compensation cost related to nonvested units				$ 10,200,000
Performance Units \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Target percentage of shares earned				0.00%
Performance Units \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Target percentage of shares earned				200.00%
2020 Directors Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of non-employee directors in committee \| director		2
Number of shares authorized to be granted \| shares		50,000
Shares remaining for future grant (in shares) \| shares				37,853
Options granted in period (in shares) \| shares				0
2020 Directors Plan \| Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price percentage of fair market value on date of grant of awards		100.00%
Award expiration date (no more than)		10 years
2020 Directors Plan \| Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award expiration date (no more than)				10 years
Award vesting period				1 year
2020 Directors Plan \| Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period				1 year
Third Amended and Restated 2007 Long-Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of non-employee directors in committee \| director			2
Number of shares authorized to be granted \| shares			6,930,000
Shares remaining for future grant (in shares) \| shares				908,753
Third Amended and Restated 2007 Long-Term Incentive Plan \| Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price percentage of fair market value on date of grant of awards				100.00%
Award expiration date (no more than)				10 years
Third Amended and Restated 2007 Long-Term Incentive Plan \| Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award expiration date (no more than)				10 years
Weighted-average fair value of each option granted (in dollars per share) \| $ / shares				$ 84.10	$ 70.45	$ 60.71
Total intrinsic value of options exercised				$ 64,700,000	$ 22,600,000	$ 40,100,000
Third Amended and Restated 2007 Long-Term Incentive Plan \| Stock Options \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period				3 years
Third Amended and Restated 2007 Long-Term Incentive Plan \| Stock Options \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period				5 years
Third Amended and Restated 2007 Long-Term Incentive Plan \| Restricted Stock Units (RSUs) \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period				3 years
Third Amended and Restated 2007 Long-Term Incentive Plan \| Restricted Stock Units (RSUs) \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period				5 years
Employee Stock Purchase Plan \| Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized to be granted \| shares	1,000,000
Exercise price percentage of fair market value on date of grant of awards	85.00%
Percentage of employees maximum eligible compensation for purchase of awards	15.00%
Amount of employees maximum eligible compensation for purchase of awards	$ 21,300
Number of shares issued to employees \| shares				17,575	11,641
Number of shares remaining available for future issuance \| shares				970,784
Share-based compensation expense				$ 1,000,000	$ 700,000
Share-Based Payment Arrangement, Nonemployee, Director \| 2020 Directors Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total grant value of awards		$ 270,000
Share-Based Payment Arrangement, Nonemployee, Lead Director \| 2020 Directors Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total grant value of awards		283,500
Share-Based Payment Arrangement, Nonemployee, Chairman \| 2020 Directors Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total grant value of awards		$ 297,000

Stock Plans - Compensation Expense and Related Income Tax Benefit for Share-Based Awards (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation expense	$ 44.7	$ 38.6	$ 36.3
Related income tax benefit	5.6	4.8	5.1
Selling, general and administrative expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation expense	38.4	32.2	28.7
Cost of sales
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation expense	3.9	4.0	4.7
Research and development expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation expense	$ 2.4	$ 2.4	$ 2.9

Stock Plans - Assumptions Used in Estimating Fair Value of Stock Options Award Granted (Details)	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life			4 years 4 months 24 days
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	4 years	4 years 4 months 24 days
Expected volatility	30.30%	24.50%	22.00%
Risk-free interest rate	0.30%	1.60%	2.90%
Dividend yield	0.02%	0.02%	0.02%

Stock Plans - Stock Option Plans (Details)	12 Months Ended
Stock Plans - Stock Option Plans (Details)	Oct. 31, 2021 USD ($) $ / shares shares
Number of Shares
Vested and expected to vest at end of period (in shares) \| shares	939,788
Vested and exercisable at end of period (in shares) \| shares	470,748
Weighted- Average Exercise Price Per Share
Vested and expected to vest at end of period (in dollars per share) \| $ / shares	$ 243.15
Vested and exercisable at end of period (in dollars per share) \| $ / shares	$ 207.13
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Vested and expected to vest at end of period, Weighted-Average Remaining Contractual Term (in years)	6 years 1 month 28 days
Vested and exercisable at end of period, Weighted-Average Remaining Contractual Term (in years)	4 years 11 months 26 days
Vested and expected to vest at end of period, Aggregate Intrinsic Value \| $	$ 163,310,445
Vested and exercisable at end of period, Aggregate Intrinsic Value \| $	$ 98,757,454
Stock Options
Number of Shares
Outstanding, beginning balance (in shares) \| shares	1,103,507
Granted (in shares) \| shares	109,440
Exercised (in shares) \| shares	(235,478)
Forfeited or expired (in shares) \| shares	(4,777)
Outstanding, ending balance (in shares) \| shares	972,692
Weighted- Average Exercise Price Per Share
Outstanding, beginning balance (in dollars per share) \| $ / shares	$ 213.53
Granted (in dollars per share) \| $ / shares	345.74
Exercised (in dollars per share) \| $ / shares	142.31
Forfeited or expired (in dollars per share) \| $ / shares	327.62
Outstanding, ending balance (in dollars per share) \| $ / shares	$ 245.09
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Outstanding, ending balance, Weighted Average Remaining Contractual Term (in years)	6 years 2 months 19 days

Stock Plans - Non-Vested RSUs (Details) - Restricted Stock Units (RSUs)	12 Months Ended
	Oct. 31, 2021 $ / shares shares
Number of Shares
Nonvested RSUs, beginning balance (in shares) \| shares	368,620
Granted (in shares) \| shares	114,111
Vested and issued (in shares) \| shares	(137,119)
Forfeited or expired (in shares) \| shares	(28,277)
Nonvested RSUs, ending balance (in shares) \| shares	317,335
Weighted- Average Grant Date Fair Value Per Share
Non-vested RSUs, beginning balance (in dollars per share) \| $ / shares	$ 247.09
Granted (in dollars per share) \| $ / shares	352.92
Vested and issued (in dollars per share) \| $ / shares	222.42
Forfeited or exercised (in dollars per share) \| $ / shares	269.62
Non-vested RSUs, ending balance (in dollars per share) \| $ / shares	$ 293.80

Employee Benefits - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Defined Benefit Plan Disclosure [Line Items]
Discount rate	2.78%	3.13%	4.42%
Discount rate, decrease	0.35%
Projected defined benefit plan benefit obligation	$ 230.2
Projected defined accumulated benefit obligation	207.0
Defined benefit obligation, actuarial gain (loss)	$ (2.0)	$ (20.0)	$ (36.6)
Expected long-term return on diversified portfolio	8.00%
Company's contribution to the pension plan	$ 12.7	23.4	13.1
Maximum annual contributions per employee in 401k savings plan	75.00%
Contributions by employer in 401k savings plan	$ 7.2	$ 6.8	$ 6.5
Minimum \| Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Diversified portfolio, allocation of assets in equities	50.00%
Maximum \| Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Diversified portfolio, allocation of assets in equities	70.00%
Change In Assumptions For Defined Benefit Plans, Change In Key Assumptions
Defined Benefit Plan Disclosure [Line Items]
Defined benefit obligation, actuarial gain (loss)	$ (0.7)
Change In Assumptions For Defined Benefit Plans, Change In Demographic Experience
Defined Benefit Plan Disclosure [Line Items]
Defined benefit obligation, actuarial gain (loss)	(1.3)
Change In Assumptions For Defined Benefit Plans, Change In Discount Rate
Defined Benefit Plan Disclosure [Line Items]
Defined benefit obligation, actuarial gain (loss)	(0.7)
Change In Assumptions For Defined Benefit Plans, Change In Lump Sum Determination
Defined Benefit Plan Disclosure [Line Items]
Defined benefit obligation, actuarial gain (loss)	0.5
Change In Assumptions For Defined Benefit Plans, Change In Mortality Assumption
Defined Benefit Plan Disclosure [Line Items]
Defined benefit obligation, actuarial gain (loss)	$ (0.5)

Employee Benefits - Changes in Benefit Obligation, Changes in Plan Assets and Funded Status (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Change in benefit obligation
Benefit obligation, beginning of year	$ 218.8	$ 189.7	$ 147.1
Service cost	17.2	13.9	10.1
Interest cost	4.4	5.2	6.1
Benefits paid	(11.5)	(10.0)	(10.2)
Actuarial loss	2.0	20.0	36.6
Benefit obligation, end of year	230.9	218.8	189.7
Change in plan assets
Fair value of plan assets, beginning of year	159.5	136.0	121.0
Actual return on plan assets	38.8	10.1	12.1
Employer contributions	12.7	23.4	13.1
Benefits paid	(11.5)	(10.0)	(10.2)
Fair value of plan assets, end of year	199.5	159.5	136.0
Funded status at end of year	$ (31.4)	$ (59.3)	$ (53.7)

Employee Benefits - Amount Recognized in the Consolidated Balance Sheets (Details) - USD ($) $ in Millions	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Amounts recognized in the Consolidated Balance Sheets consist of:
Noncurrent liabilities	$ (31.4)	$ (59.3)	$ (53.7)
Net amount recognized at year end	$ (31.4)	$ (59.3)	$ (53.7)

Employee Benefits - Amounts Recognized in Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Amounts recognized in accumulated other comprehensive income consist of:
Net loss	$ 44.4	$ 74.2	$ 57.3
Accumulated other comprehensive income	$ 44.4	$ 74.2	$ 57.3

Employee Benefits - Pension Plans with Projected Benefit Obligation in Excess of Plan Assets (Details) - USD ($) $ in Millions	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Information for defined benefit plans with projected benefit obligation in excess of plan assets:
Projected benefit obligation	$ 230.9	$ 218.8	$ 189.7
Fair value of plan assets	$ 199.5	$ 159.5	$ 136.0

Employee Benefits - Pension Plans with Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets (Details) - USD ($) $ in Millions	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Information for defined benefit plans with accumulated benefit obligations in excess of plan assets:
Accumulated benefit obligation	$ 207.6	$ 195.8	$ 170.8
Fair value of plan assets	$ 199.5	$ 159.5	$ 136.0

Employee Benefits - Reconciliation of Prepaid (Accrued) Pension Cost (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Reconciliation of (prepaid) accrued pension cost:
(Prepaid)/Accrued pension cost at prior fiscal year end	$ (14.8)	$ (3.7)	$ 2.2
Net periodic benefit cost	14.5	12.3	7.2
Contributions made during the year	(12.7)	(23.4)	(13.1)
(Prepaid)/Accrued pension cost at fiscal year end	$ (13.0)	$ (14.8)	$ (3.7)

- Definition

Amount of contribution received by defined benefit plan from employer which increases plan assets.

+ References + Details

Employee Benefits - Components of Net Periodic Pension Costs and Other Amounts Recognized in Other Comprehensive Income (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Components of net periodic benefit cost and other amounts recognized in the Consolidated Statements of Income:
Service cost	$ 17.2	$ 13.9	$ 10.1
Interest cost	4.4	5.2	6.1
Expected return on plan assets	(12.5)	(10.8)	(9.8)
Recognized actuarial loss	5.4	4.0	0.8
Net periodic pension cost	$ 14.5	$ 12.3	$ 7.2

Employee Benefits - Other Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Income (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Other changes in plan assets and benefit obligations recognized in other comprehensive income:
Net (gain) loss	$ (24.4)	$ 20.8	$ 34.2
Amortizations of net gain	(5.4)	(4.0)	(0.8)
Total recognized in other comprehensive (income) loss	(29.8)	16.8	33.4
Total recognized in net periodic benefit cost and other comprehensive (income) loss	$ (15.2)	$ 29.0	$ 40.6

Employee Benefits - Weighted-Average Assumptions Used in Computing Net Periodic Pension Cost and Projected Benefit Obligation (Details)	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Discount rate for determining net periodic pension cost:
Projected Benefit Obligation	2.78%	3.13%	4.42%
Service Cost	2.86%	3.18%	4.49%
Interest Cost	2.07%	2.78%	4.22%
Discount rate for determining benefit obligations at year end	2.76%	2.78%	3.13%
Rate of compensation increase for determining expense	3.60%	3.60%	4.00%
Rate of compensation increase for determining benefit obligations at year end	3.60%	3.60%	3.60%
Expected rate of return on plan assets for determining net periodic pension cost	8.00%	8.00%	8.00%
Expected rate of return on plan assets at year end	8.00%	8.00%	8.00%

Employee Benefits - Weighted-Average Asset Allocations by Asset Category (Details)	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Defined Benefit Plan, Plan Assets, Allocation [Line Items]
Asset allocation	100.00%	100.00%	100.00%
Cash and cash equivalents
Defined Benefit Plan, Plan Assets, Allocation [Line Items]
Asset allocation	5.00%	11.80%	3.20%
Equity mutual funds
Defined Benefit Plan, Plan Assets, Allocation [Line Items]
Asset allocation	62.80%	57.70%	63.70%
Hedging Strategy Funds
Defined Benefit Plan, Plan Assets, Allocation [Line Items]
Asset allocation	4.70%	4.30%	4.90%
Bond mutual funds
Defined Benefit Plan, Plan Assets, Allocation [Line Items]
Asset allocation	27.50%	26.20%	28.20%

Employee Benefits - Fair Value Measurement of Plan Assets (Details) - USD ($) $ in Millions	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2018
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	$ 199.5	$ 159.5	$ 136.0	$ 121.0
Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	169.2
Significant Observable Inputs (Level 2)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	30.2
Significant Unobservable Inputs (Level 3)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	0.1
Cash and cash equivalents
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	10.0
Cash and cash equivalents \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	10.0
Cash and cash equivalents \| Significant Observable Inputs (Level 2)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	0.0
Cash and cash equivalents \| Significant Unobservable Inputs (Level 3)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	0.0
Equity mutual funds
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	125.3
Equity mutual funds \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	125.3
Equity mutual funds \| Significant Observable Inputs (Level 2)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	0.0
Equity mutual funds \| Significant Unobservable Inputs (Level 3)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	0.0
Hedging Strategy Funds
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	9.4
Hedging Strategy Funds \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	9.4
Hedging Strategy Funds \| Significant Observable Inputs (Level 2)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	0.0
Hedging Strategy Funds \| Significant Unobservable Inputs (Level 3)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	0.0
Bond mutual funds
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	54.8
Bond mutual funds \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	24.5
Bond mutual funds \| Significant Observable Inputs (Level 2)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	30.2
Bond mutual funds \| Significant Unobservable Inputs (Level 3)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	$ 0.1

- Definition

Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.

+ References + Details

Employee Benefits - Estimated Future Benefit Payments (Details) $ in Millions	Oct. 31, 2021 USD ($)
Defined Benefit Plan, Expected Future Benefit Payment [Abstract]
2022	$ 10.7
2023	11.6
2024	12.8
2025	13.7
2026	14.4
2027-2031	$ 79.6

Fair Value Measurements (Details) - Interest Rate Swap		9 Months Ended
Fair Value Measurements (Details) - Interest Rate Swap	Apr. 06, 2020 USD ($) interest_rate_swap_contract	Jul. 31, 2021	Oct. 31, 2021 USD ($) interest_rate_swap_contract
Derivative [Line Items]
Number of interest rate swap contracts held	6
Derivative, term of contract (or less)	7 years	6 years
Number of interest rate swap contracts matured			3
Derivative notional amount \| $	$ 1,500,000,000		$ 1,000,000,000

Business Segment Information - Narrative (Details)	12 Months Ended
Business Segment Information - Narrative (Details)	Oct. 31, 2021 segment
Segment Reporting [Abstract]
Number of operating segments	2

Business Segment Information - Business Segment Net Sales (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Segment Reporting Information [Line Items]
Net sales	$ 2,922.5	$ 2,430.9	$ 2,653.4
CooperVision
Segment Reporting Information [Line Items]
Net sales	2,152.0	1,843.0	1,972.9
CooperSurgical
Segment Reporting Information [Line Items]
Net sales	770.5	587.9	680.5
Toric lens \| CooperVision
Segment Reporting Information [Line Items]
Net sales	697.5	598.2	620.0
Multifocal lens \| CooperVision
Segment Reporting Information [Line Items]
Net sales	238.6	197.0	202.9
Single-use sphere lens \| CooperVision
Segment Reporting Information [Line Items]
Net sales	616.3	529.0	568.2
Non single-use sphere, other \| CooperVision
Segment Reporting Information [Line Items]
Net sales	599.6	518.8	581.8
Office and surgical products \| CooperSurgical
Segment Reporting Information [Line Items]
Net sales	451.3	358.8	422.4
Fertility \| CooperSurgical
Segment Reporting Information [Line Items]
Net sales	$ 319.2	$ 229.1	$ 258.1

Business Segment Information - Business Segment Information (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Segment Reporting Information [Line Items]
Net sales	$ 2,922.5	$ 2,430.9	$ 2,653.4
Operating income (loss)	505.8	311.8	546.7
Interest expense	23.1	36.8	68.0
Other expense (income), net	(8.8)	8.5	1.3
Income before income taxes	491.5	266.5	477.4
Identifiable assets	9,606.2	6,737.5	6,274.5
Depreciation expense	163.2	149.9	135.0
Amortization expense	146.1	137.2	145.8
Capital expenditures	214.4	310.4	292.1
CooperVision
Segment Reporting Information [Line Items]
Net sales	2,152.0	1,843.0	1,972.9
CooperSurgical
Segment Reporting Information [Line Items]
Net sales	770.5	587.9	680.5
Corporate
Segment Reporting Information [Line Items]
Net sales	0.0	0.0	0.0
Operating income (loss)	(47.3)	(49.2)	(47.6)
Identifiable assets	244.7	207.4	173.1
Depreciation expense	0.0	0.0	0.2
Amortization expense	0.0	0.0	0.0
Capital expenditures	0.0	0.0	0.0
Operating Segments \| CooperVision
Segment Reporting Information [Line Items]
Net sales	2,152.0	1,843.0	1,972.9
Operating income (loss)	481.3	375.7	506.4
Identifiable assets	6,965.9	4,236.3	3,911.6
Depreciation expense	148.3	138.2	125.8
Amortization expense	35.7	32.4	40.9
Capital expenditures	190.0	260.3	259.0
Operating Segments \| CooperSurgical
Segment Reporting Information [Line Items]
Net sales	770.5	587.9	680.5
Operating income (loss)	71.8	(14.7)	87.9
Identifiable assets	2,395.6	2,293.8	2,189.8
Depreciation expense	14.9	11.7	9.0
Amortization expense	110.4	104.8	104.9
Capital expenditures	$ 24.4	$ 50.1	$ 33.1

Business Segment Information - Information by Geographical Area by Country of Domicile (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Segment Reporting Information [Line Items]
Net sales	$ (2,922.5)	$ (2,430.9)	$ (2,653.4)
Operating (loss) income	505.8	311.8	546.7
Long-lived assets	1,347.6	1,281.9	1,132.1
United States
Segment Reporting Information [Line Items]
Net sales	(1,339.2)	(1,103.6)	(1,211.8)
Europe
Segment Reporting Information [Line Items]
Net sales	(957.9)	(789.8)	(854.8)
Rest of World
Segment Reporting Information [Line Items]
Net sales	(625.4)	(537.5)	(586.8)
Geography Eliminations \| United States
Segment Reporting Information [Line Items]
Net sales	494.9	391.7	650.7
Geography Eliminations \| Europe
Segment Reporting Information [Line Items]
Net sales	815.1	327.1	300.8
Geography Eliminations \| Rest of World
Segment Reporting Information [Line Items]
Net sales	1,310.0	718.8	951.5
Reportable Geographical Components \| United States
Segment Reporting Information [Line Items]
Net sales	(1,834.1)	(1,495.3)	(1,862.5)
Operating (loss) income	(26.8)	(14.5)	83.2
Long-lived assets	737.5	721.3	626.5
Reportable Geographical Components \| Europe
Segment Reporting Information [Line Items]
Net sales	(1,773.0)	(1,116.9)	(1,155.6)
Operating (loss) income	416.2	21.9	29.3
Long-lived assets	377.2	363.0	358.8
Eliminations, Corporate and Reconciling Items \| Rest of World
Segment Reporting Information [Line Items]
Net sales	684.6	181.3	364.7
Operating (loss) income	116.4	304.4	434.2
Long-lived assets	$ 232.9	$ 197.6	$ 146.8

Financial Derivatives and Hedging - Outstanding Derivatives Designated as Hedging Instruments (Details) - Interest Rate Swap	Oct. 31, 2021 USD ($) interest_rate_swap_contract	Apr. 06, 2020 USD ($)
Derivative [Line Items]
Number of Instruments \| interest_rate_swap_contract	3
Notional Value \| $	$ 1,000,000,000	$ 1,500,000,000

Financial Derivatives and Hedging - Narrative (Details) - USD ($) $ in Millions		9 Months Ended	12 Months Ended
	Apr. 06, 2020	Jul. 31, 2021	Oct. 31, 2021	Oct. 31, 2020
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Pre-tax impact of gain (loss) on derivatives recognized in other comprehensive income (loss)			$ 17.2	$ (17.1)
Gain (loss) on derivatives recognized in other comprehensive income (loss), net of tax			13.1	$ (13.0)
Derivative loss expected to be realized in earnings over the next twelve months			$ 5.1
Interest Rate Swap
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swap contracts, contract term (or less)	7 years	6 years

Financial Derivatives and Hedging - Fair Values of Derivative Instruments in Condensed Consolidated Balance Sheets (Details) - Designated as Hedging Instrument - Interest Rate Swap - USD ($) $ in Millions	Oct. 31, 2021	Oct. 31, 2020
Derivative Asset [Abstract]
Interest rate swap contracts	$ 17.2	$ 0.0
Derivative Liability [Abstract]
Interest rate swap contracts	0.0	17.1
Other current assets
Derivative Asset [Abstract]
Interest rate swap contracts	0.0	0.0
Other non-current assets
Derivative Asset [Abstract]
Interest rate swap contracts	17.2	0.0
Other current liabilities
Derivative Liability [Abstract]
Interest rate swap contracts	0.0	0.6
Other non-current liabilities
Derivative Liability [Abstract]
Interest rate swap contracts	$ 0.0	$ 16.5

Financial Derivatives and Hedging - Derivative Instruments Recognized in Condensed Consolidated Statements of Income (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Interest expense \| Interest Rate Swap
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Loss recognized on derivatives within interest expense	$ 8.0	$ 3.7	$ 0.0

Financial Derivatives and Hedging - Changes in Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
AOCI Attributable To Parent, Before Reclassification And Tax [Roll Forward]
Beginning balance	$ 3,824.8	$ 3,628.6	$ 3,307.8
Amount recognized in other comprehensive income on interest rate swaps contracts, net of tax	20.0	(15.8)
Amount reclassified from other comprehensive income into earnings, net of tax	6.1	2.8
Ending balance	6,942.0	3,824.8	3,628.6
Accumulated Gain (Loss), Net, Cash Flow Hedge, Before Tax, Parent
AOCI Attributable To Parent, Before Reclassification And Tax [Roll Forward]
Beginning balance	(17.1)	0.0
Ending balance	17.2	(17.1)	0.0
Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent
AOCI Attributable To Parent, Before Reclassification And Tax [Roll Forward]
Beginning balance	(13.0)	0.0	0.0
Amount recognized in other comprehensive income on interest rate swap contracts, gross	26.3	(20.8)
Amount reclassified from other comprehensive income into earnings, gross	8.0	3.7
Ending balance	$ 13.1	$ (13.0)	$ 0.0

- Definition

+ References

+ Details

Subsequent Events (Details) - Subsequent Event - USD ($)		3 Months Ended
	Nov. 02, 2021	Jan. 31, 2022
Forecast \| Generate Life Sciences
Subsequent Event [Line Items]
Payments to acquire business		$ 1,605,000,000
Term Loan Agreement 2021 \| Term loans
Subsequent Event [Line Items]
Debt term	364 days
Original debt amount	$ 840,000,000
Term Loan Agreement 2021 \| Term loans \| London Interbank Offered Rate (LIBOR)
Subsequent Event [Line Items]
Debt instrument, basis spread on variable rate	0.60%

Schedule II - Valuation and Qualifying Accounts for Allowance for Doubtful Accounts (Details) - SEC Schedule, 12-09, Allowance, Credit Loss - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance Beginning of Year	$ 10.2	$ 16.4	$ 19.0
Additions Charged to Costs and Expenses	0.7	3.6	1.6
(Deductions) Recoveries/ Other	(1.7)	(9.8)	(4.2)
Balance at End of Year	$ 9.2	$ 10.2	$ 16.4

Schedule II - Valuation and Qualifying Accounts for Deferred Income Tax Valuation Allowance (Details) - SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Balance Beginning of Year	$ 45.3	$ 41.5	$ 39.1
Additions	8.8	5.9	3.9
Reductions/ Charges	(2.3)	(2.1)	(1.5)
Balance at End of Year	$ 51.8	$ 45.3	$ 41.5

Label	Element	Value
Accounting Standards Update [Extensible Enumeration]	us-gaap_AccountingStandardsUpdateExtensibleList	Accounting Standards Update 2016-16 1 [Member]

- Definition

Indicates amendment to accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 7
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(3)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S65
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 45: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 49: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 50: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 51: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 52: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 53: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 54: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 55: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(4)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 56: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 57: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 58: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 59: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 60: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 61: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (a)

Reference 62: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (a)(1)

Reference 63: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (a)(2)

Reference 64: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (a)(3)(iii)(01)

Reference 65: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (a)(3)(iii)(03)

+ Details